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ABSTRACT 
 
THE ROLE OF ERK5 IN DOPAMINE NEURONAL SURVIVAL 
 
 
 
By 
Mayur S. Parmar 
May 2014 
 
Dissertation supervised by Jane E. Cavanaugh, Ph.D 
 The extracellular signal-regulated kinases (ERKs) 1, 2, and 5 play important 
physiological roles in neurogenesis, neutrite outgrowth, and neuronal viability in the 
central nervous system. In this study, ERK1, 2, and 5 expression and activation were 
examined in the substantia nigra (SN), striatum (STR), and ventral tegmental area (VTA) 
during postnatal development and normal aging using western blot analysis. An age-
related decrease in phosphorylated/activated ERK5 (p-ERK5) was observed in the SN 
and STR, whereas an increase in total ERK1 was observed in all three regions.  Higher 
expression of total and phosphorylated ERK5 was observed at postnatal day zero (PND0) 
in all dopaminergic regions, which declined with the postnatal development. However, 
expression of total ERK1 and ERK2 increased with the postnatal development.  An 
increase in the p-ERK1 and p-ERK2 peak was observed in both dopaminergic cell bodies 
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containing regions, SN and VTA at PND7 as compared to PND0. In contrast, no such 
peak was observed in the STR with the postnatal development. 
In primary DA cultures of the SN and VTA, inhibition of ERK5 but not ERK1 
and ERK 2 activation significantly decreased DA neuronal viability. Pretreatment with 
the glial cell line-derived neurotrophic factor (GDNF) or dopamine neuron stimulating 
peptide-11 (DNSP-11) did not protect human dopaminergic SH-SY5Y cells against 6-
hydroxydopamine (6-OHDA)-induced toxicity at 24 h. However, GDNF or DNSP-11 
pretreatment protected against 6-OHDA-induced increase in apoptotic signaling, as 
measured by caspase-3/7 activity at 6 h; indicating that GDNF and DNSP-11 blocks 
some, but not all, of the cytotoxic effects of 6-OHDA. Treatment of SH-SY5Y cells with 
GDNF or DNSP-11 resulted in activation of ERK1, 2, and 5 signaling.  Infusion of 
DNSP-11 into the STR also resulted in modulation of ERK1, 2, and 5 signaling. Increase 
in tyrosine hydroxylase expression was observed in the STR (42%) and SN (32%), at 7 
days and 6 h, respectively, after DNSP-11 infusion. 
Together, these data suggest the essential role of ERK1, 2, and 5 kinases in 
dopamine neuronal survival, especially ERK5. These data raise the possibility that a 
decline ERK5 signaling may play a role in age-related impairments in dopaminergic 
function. 
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Chapter 1: Introduction 
1.1 Overview 
 
In United States, people aged 65 years or older represents 12.8% (~39.2 million) 
of the total population (US Census 2011). These data indicate that one in every eight 
American is aged > 65 years. From 2010 to 2040, a large number of “baby boomers” is 
projected to reach age 65; thus, by 2040, there will be approximately 79 million people 
age 65 or older, a 21% rise from the current population. 
As the population ages, an increase in the number of people suffering from 
neurodegenerative diseases is expected to rise due to nervous system dysfunction. An 
increase in the aging population is considered to be the biggest health challenge in terms 
of occurrence of neurodegenerative diseases. Moreover, this rise in the aging population 
will cost the U.S. economy billions of dollars each year, resulting from direct health costs 
and an overall decline in work opportunities.  
At the cellular and molecular level, alterations occurring with aging include an 
accumulation of reactive oxygen species, a reduction in cellular antioxidant levels, and a 
decline in mitochondrial function and pro-survival cellular signaling (Mariani et al., 
2005; Lin et al., 2006). Furthermore, clearance of misfolded proteins does not occur 
effectively (Wang et al., 2006). The nervous system is particularly vulnerable to the 
above mentioned deleterious age-related changes, which could result in the development 
of neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), and Amyotrophic lateral sclerosis (ALS) (Andersen, 2004; Mariani et al., 2005; Lin 
et al., 2006; Wang et al., 2006). In these neurodegenerative diseases, both increased 
neuronal function impairment and neuronal cell-death are observed. Over the next several 
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decades, the occurrence of neurodegenerative diseases is anticipated to rise due to 
increasing life expectancies in industrialized nations resulting in a larger aged population. 
With normal aging, a progressive loss of dopamine neurons is observed in the 
substantia nigra (SN) of the brain. This neuronal loss results in dopaminergic nervous 
system dysfunction, which makes a person more susceptible to developing PD. 
Parkinson’s disease is the second most common neurodegenerative disease after AD. The 
principle risk factor for PD is age, with incidence rising after age 60, peaking between 
ages 85-89, and then declining after the age of 90 (Driver et al., 2009). PD affects more 
than 1% of people over the age of 65 and 4% of the population is afflicted by the age of 
85 years. Clinically, PD is defined by the presence of the following motor signs: 
bradykinesia, rigidity, tremor, and postural instability (Burke and O'Malley, 2012). These 
motor declines are associated with the loss of the dopamine neurons in the SN and 
reduced striatal dopamine neurotransmitter levels (Burke and O'Malley, 2012). Non-
motor features are also observed during the course of this disease, including cognitive 
impairment, depression, insomnia, and anxiety (Chaudhuri et al., 2006). At the time of 
PD symptom onset, the loss of dopamine neurons in the SN is ~ 30%, while the decline 
in striatal dopamine levels is 50-60% as compared to age-matched controls (Burke and 
O'Malley, 2012).  
Numerous studies have focused on understanding the dopaminergic 
neuroprotective properties of neurotrophic factors, neurotrophins, and phytochemicals 
against several neurotoxins (Spina et al., 1992; Fox et al., 2001; Guo et al., 2007) in order 
to define therapeutic agents to halt progressive loss of DA neurons in PD. However, our 
understanding of the cellular and molecular mechanisms underlying the basal survival of 
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dopamine neurons is not clear. Moreover, the changes in expression and activation of 
signaling pathways during postnatal development of dopaminergic neurons and normal 
aging have been not observed. In this study, an effort was made to elucidate the age-
related cellular signaling changes, specifically mitogen activated protein kinases 
(MAPKs), in the dopaminergic system, which includes the substantia nigra, ventral 
tegmental area, and striatum. The role of mitogen activated protein kinases (MAPKs), 
namely, the extracellular signal-regulated kinases (ERK) 1, 2, and 5 were studied. These 
signaling pathways are known to protect dopamine neurons against neurotoxins (Ugarte 
et al., 2003; Cavanaugh, 2004; Lindgren et al, 2008). The cellular role of these signaling 
pathways in the basal survival of dopamine neurons were investigated by blocking their 
activation/phosphorylation. 
Glial cell line-derived neurotrophic factor (GDNF) and dopamine neuron 
stimulating peptide-11 (DNSP-11) have been shown to be important for the basal survival 
of dopamine neurons in vitro (Lin et al., 1993; Bradley et al., 2010) and for protection 
against neurotoxins both in vitro and in vivo (Fox et al, 2001; Bradley et al., 2010; Sonne, 
2013). However, the cellular and molecular mechanisms underlying these 
neuroprotective properties are not clear. Hence, this research aimed to understand the 
cellular signaling pathways that are activated by GDNF or DNSP-11 in vitro and in vivo. 
Also, it was tested whether GDNF or DNSP-11 protects human dopaminergic SH-SY5Y 
cells against 6-hydrodopamine (6-OHDA)-induced toxicity. Overall, the goal of this 
dissertation project is to understand the cellular signaling pathways that are important for 
basal dopaminergic neuronal survival, and elucidate whether activation of these signaling 
pathways is crucial for therapeutic agent-mediated dopaminergic protection.  
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1.2  The dopamine system 
1.2.1 Dopamine 
 
Dopamine (DA) is the neurotransmitter that plays a crucial role in regulating 
motor coordination (DeLong, 1990; Graybiel et al., 1994), learning and memory 
(Kulisevsky, 2000), and the sleep-wake cycle (Dzirasa et al., 2006). Dysfunctioning of 
the dopamine system is known to be associated with numerous psychiatric and 
neurodegenerative disorders, including schizophrenia, and Parkinson’s disease (PD). 
1.2.1.1 Dopamine Synthesis, Release, Uptake, and Metabolism 
 
Dopamine is a catecholamine synthesized from the amino acid precursor tyrosine. 
Tyrosine is a non-essential amino acid that is taken up through the blood-brain barrier by 
a transporter into the dopaminergic neurons. DA is then synthesized in a two-step process 
(Fig. 1). In the cytoplasm of a DA neuron, tyrosine is converted into L-3, 4-
dihydroxyphenylalanine (L-DOPA) through an enzymatic reaction with tyrosine 
hydroxylase (TH), the rate limiting enzyme in DA synthesis. L-DOPA is then converted 
into cytosolic DA by aromatic amino acid decarboxylase (AADC). The activity of TH is 
regulated by phosphorylation of 3 sites (ser19, ser31, ser40). The amount of DA 
synthesized is dependent on the modulation of TH activity. Once DA is synthesized, it is 
transported into the synaptic vesicles by the vesicular monoamine transporter 2 
(VMAT2). Hence, the cytosolic DA concentrations are normally quite low. Further, this 
transport of DA into vesicles protects it from catabolizing enzymes. When an action 
potential arrives at the axon terminal, the synaptic vesicles fuse with the plasma 
membrane and release DA into the extracellular space between the presynaptic and 
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postsynaptic neurons (the synaptic cleft) at a rate proportional to the firing rate of the 
neuron. 
Once DA is released from the presynaptic neuron, it is rapidly taken up from the 
extracellular space by the DA transporters (DATs) that are present on the plasma 
membrane of the presynaptic terminals. This uptake of DA by the DAT is important for 
maintaining the homeostasis of extracellular DA. DA is also removed from the 
extracellular space by uptake into glial cells and blood and diffusion out of the striatum.  
The binding of DA to a presynaptic DA autoreceptor regulates DA synthesis by 
modulating TH activity. It has been reported that an increase in extracellular DA can 
result in inhibition of TH by 50%, while a reduction of extracellular DA levels leads to an 
increase in DA synthesis by a factor of 4 to 5 (Best et al., 2009).  
Inside dopaminergic neurons, DA is mainly catabolized by two successive 
reactions (Fig. 1). First, monoamine oxidase (MAO-A) present in the cytosol transforms 
DA into the corresponding aldehyde, which then acts as a substrate for aldehyde 
dehydrogenase to produce 3,4-dihydroxyphenylacetic acid (DOPAC). The metabolite 
DOPAC diffuses out of the neuron into the synaptic cleft, where it is either conjugated 
with glucuronides or metabolized to 3-methoxytyramine (3-MT) by catechol-O-
methyltransferase (COMT) that is only present outside dopaminergic neurons. This 3-MT 
is then oxidized by MAO-B, which is present in non-neuronal cells such as astrocytes and 
glia (Mallajosyula et al., 2008), to form HVA.  
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Figure 1: The pathway of dopamine synthesis, release, uptake, and metabolism 
TH-Tyrosine hyroxylase; AADC-aromatic amino acid decarboxylase; L-DOPA-L-3, 4-
dihydroxyphenylalanine; DA- dopamine; DAT- dopamine transporter;  
MAO - monoamine oxidase; COMT-catechol-O-methyltransferase; DOPAC - 3, 4-
dihydroxyphenylacetic acid; HVA- homovanillic acid; 3-MT-3-methoxytyramine. 
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Since DOPAC results from newly synthesized DA through the activity of MAO-
A which is present inside the dopaminergic neuron, measurement of DOPAC levels 
indicate the amount of DA synthesized. Overall, measurement of the turnover ratio of DA 
metabolites [DOPAC/DA, HVA/DA, and (DOPAC+HVA)/DA] is indicative of the 
activity of dopaminergic neurons. At the steady state in the brain, the measured 
concentration of 3-MT is quite low due to the lower concentration of the extracellular DA 
and fast interaction with the MAO-B to form HVA (Sotnikova et al., 2010). Previously, 
several studies analyzed 3-MT as the indicator of DA release in various experimental 
paradigms (Kehr, 1981); however, the use of in vivo microdialysis has established that 
the measurement of 3-MT accumulation is an inaccurate measure of DA release (Vulto et 
al., 1986; Elverfors et al., 1997; Sotnikova et al., 2010). 
The physiological effects of DA are mediated by two main DA receptor subtypes, 
namely D1- and D2. The D1-like receptors subtypes are D1 and D5, while the D2-like 
receptors subtypes include D2, D3, and D4 (Jaber et al. 1997). These receptors are a 
group of G-protein-coupled receptors (GPCRs) with 7 transmembrane domains. The D1-
type receptors are positively coupled to adenylyl cyclase and the D2-like receptors are 
negatively coupled to adenylyl cyclase. The distribution of the DA receptors across the 
dopaminergic system differs. The D1-like receptors are present in both dorsal and ventral 
striatum, and are expressed mainly in the GABAergic medium-size spiny neurons 
expressing substance P and dynorphin (Jaber et al., 1996). The D2-like receptors are also 
expressed in the dorsal and ventral striatum, but they are expressed in the GABAergic 
neurons expressing pre-proenkephalin (Jaber et al. 1996). Among all the DA receptor 
subtypes, D1 and D2 are the most abundant subtypes in the CNS (Jaber et al., 1996)  
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In the dopaminergic system, the three distinct nuclei that contain DA neuronal 
cell bodies are the retrorubral field (RrF, A8), substantia nigra pars compacta (SNc, A9), 
and the ventral tegmental area (VTA, A10) (Prakash and Wurst, 2006). The majority of 
DA neurons reside in the SNc and VTA. The dopamine neurons in the SN and VTA are 
distinct in terms of neurophysiological properties; vulnerability, protein expression, and 
sensitivity towards neurotoxins (German et al., 1989; Ding et al., 2004; Korotkova et al., 
2005; Tagliaferro and Burke, 2010). 
1.2.2 Basal Ganglia 
 
In mammals, the basal ganglia consist of group of subcortical nuclei beneath the 
cortex. Information from the cortices are channeled to the basal ganglia input nuclei [i.e. 
striatum (caudate nucleus and putamen) and the subthalamic nucleus (STN)], and the 
information is then relayed to the basal ganglia output nuclei [i.e. the substantia nigra 
pars reticulata (SNr) and the internal globus pallidus (GPi in primates, GPm in rodents)]. 
The information from basal ganglia input to the output nuclei is relayed by the 
GABAergic external globus pallidus (GPe in primates, GP in rodents) and glutamatergic 
subthalamic nucleus (STh) (Hardman et al., 2002).  The caudate, putamen, and nucleus 
accumbens nuclei in the basal ganglia process information received from the central 
nervous system, particularly the cortex. Within the basal ganglia are groups of neurons - 
dopaminergic, γ-aminobutyric acid (GABA)-ergic, norepinephrine (NE), cholinergic, and 
serotonin (5-HT) neurons. The input nucleus (i.e. the striatum) and the output nuclei (i.e. 
the SNr) of the basal ganglia are widely studied across various mammalian species 
(Hardman et al., 2002).   
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Figure 2: Tyrosine hydroxylase (TH) immunostaining of dopamine neurons in the 
substantia nigra (SN) and ventral tegmental area (VTA) 
A) Twenty-five µm coronal rat brain section through midbrain was immunostained for 
TH protein using primary TH (Millipore, Cat. No. MAB318, Mouse source, 1:1000) 
antibody followed by detection using secondary infrared goat anti-mouse (Licor 
biosciences, Cat. No. 926-32210, 1:10,000). Section was scanned on Odyssey scanner 
(Licor Biosciences). B) Twenty-five µm coronal rat brain section through midbrain was 
stained for TH protein using primary TH (Millipore, Cat. No. MAB318, Mouse source, 
1:1000) antibody followed by detection using secondary goat anti-mouse (Invitrogen, 
Alexa Fluor
®
 488, Cat. No. A-11001, 1:1,000) antibody. Section was scanned on EVOS 
epifluorescent microscope (Model #AMF-4301-US, Advanced Microscopy Group).  
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1.2.3  Substantia Nigra (SN) 
 
The substantia nigra is divided into two main, distinct areas, called SN pars 
compacta (SNc) and SN pars reticulata (SNr) (Fig. 2).  The SNc contains densely packed 
cell bodies of dopaminergic neurons of many shapes and sizes as compared to more 
diffuse, triangular or round cell bodies in the SNr (Poirier et al., 1983; Robinson et al., 
2012) The SNr is comprised primarily of GABAergic neurons arranged in dorsoventrally 
elongated clusters and they occupy DA-cell free regions (Gonzalez-Hernandez et al., 
2000; Robinson et al., 2012). Dopaminergic neurons arising from the SNc send their 
projections to the dorsal striatum, particularly the caudate and putamen, forming the 
nigrostriatal pathway. The nigrostriatal pathway controls voluntary movements and its 
degeneration in humans leads to PD.  The dopaminergic neurons in the SNc are 
modulated in terms of dopaminergic release and activation, through GABAergic input 
from the SNr and feedback from the striatum. The loss of DA neurons in these regions 
with age, or during neurodegenerative disease, disrupts basal ganglia circuitry resulting in 
a loss of regulatory control of DA on to the GABAergic fibers, thereby, negatively 
affecting motor coordination. 
From a post-mortem brain study, it was found that the loss of DA neurons in the 
SNc is up to 0.5 to 0.7 % annually (i.e. 5 – 7% per decade) (Seidler et al., 2010).  
However, the age-related loss of DA neurons is controversial, such that some groups 
have noted a significant decline in TH
+
 DA neurons with age (McGeer et al., 1977; 
Fearnley and Lees, 1991; Emborg et al., 1998; Gerhardt et al., 2002), while others noted 
no age-related decline in TH
+
 DA neurons (Wolf et al., 1991; Kubis et al., 2000). The DA 
neurons in the SNc can be sub-classified into dorsal and ventral tier based upon the 
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morphological features, neuronal projections, and patterns of protein expression (Gerfen 
et al., 1987). The dorsal tier of the SNc contained a dense collection of DA neurons 
(round or fusiform in shape) (Tagliaferro and Burke, 2010). These DA neurons project 
dendrites mediolaterally and innervate the striatal matrix compartments (Gerfen et al., 
1987) and in turn receive input from the limbic patch compartment (Neuhoff et al., 2002).  
These neurons are calcium-binding protein calbindin positive (CB+) and express low 
levels of DAT (Neuhoff et al., 2002; Tagliaferro and Burke, 2010). While the ventral tier 
of the SNc contained a sheet of densely packed angular cells of DA neurons (Gerfen et 
al., 1987). The DA neurons of ventral tier SNc and SNr projects to the striatal patch 
compartments and in turn receive information from striatal projection neurons in the 
matrix (Neuhoff et al., 2002). The ventral tier neurons express aldehyde dehydrogenase 
1A1 (ALHD1A1 or AHD2) and DAT (Tagliaferro and Burke, 2010). The DA neurons in 
the ventral tier are more vulnerable to neurotoxin 6-hydroxyamine toxicity (Gerfen et al., 
1987) and are thought to be more vulnerable in neurodegenerative diseases such as PD 
(German et al., 1989).  This vulnerability difference is thought to be due to the higher 
expression levels of calbindin in the SNc dorsal tier neurons.  
1.2.4  Ventral Tegmental Area (VTA) 
 
Dopaminergic neurons arising from the VTA send their projections to the ventral 
striatum (Fig. 3), particularly the nucleus accumbens, olfactory tubercle, and other limbic 
structures, such as amygdala and hippocampus, forming the mesolimbic pathway. 
Dopaminergic neurons from the VTA also send projections to the cortical areas, such as 
the medial prefrontal and entorhinal cortex, forming the mesocortical dopaminergic 
pathway. In the VTA, a large network of GABAergic neurons is present, along with a 
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small percentage of excitatory glutaminergic neurons. Dysfunction of this mesolimbic 
pathway has been implicated in psychiatric disorders such as schizophrenia and drug 
addiction. The DA neurons of VTA are less vulnerable or largely spared during 
neurotoxicity or neurodegenerative diseases such as PD (German et al., 1989; Ding et al., 
2004; Di Salvio et al., 2010). Interestingly, the expression of calbindin is four times 
higher in the VTA relative to the SN (Korotkova et al., 2005). It is thought that the higher 
co-expression of this neuroprotective protein calbindin and transcription factors, such as 
Pitx3, in the VTA as compared to the SN may contribute to the different vulnerability of 
these dopaminergic neurons (Korotkova et al., 2005). Recently, Di Salvio et al. (2010) 
reported that the presence of the transcription factor Otx2 in the VTA conferred 
resistance to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-HCl (MPTP) toxicity.  
Moreover, it has been suggested that the lower expression of DAT in the VTA as 
compared to the SN also contributes to the lower vulnerability of the VTA to 
neurotoxins. 
1.2.5  Striatum (STR) 
 
The striatum is the largest subcortical nuclei structure of the basal ganglia system 
associated with motor planning, and motivation. It consists of the caudate nucleus and 
putamen. In primates, the caudate nucleus and putamen are separated by the internal 
capsule, while in rodents both regions are indistinguishable. In the rat, the striatum is 
divided into two subdivisions: a dorsal striatum that contains most of the caudate and 
putamen, and a ventral striatum, which contains the nucleus accumbens, as well as part of 
the olfactory tubercle (Fig. 3). The primary dopaminergic input to the dorsal striatum 
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arises from the SNc, while the primary dopaminergic input to the ventral striatum arises 
from the VTA.  
The striatum contains two distinct areas, called the striatal matrix and the striatal 
patches. These areas are divided based on the absence or presence of 
acetylcholinesterase. The striatal patch lacks acetylcholinesterase and thus has a high 
concentration of acetylcholine. It is primarily innervated by limbic associated areas such 
as the hippocampus. On other hand, the striatal matrix has a high concentration of 
acetylcholinesterase and thus is a choline-rich environment. It is primarily innervated by 
cortical and thalamic glutamatergic projections (Gerfen et al., 1992) Dopamine afferents 
to the striatal matrix originate from the VTA, dorsal tier SNc, and retrorubral nucleus, 
while dopamine afferents to the striatal patches arise from the ventral tier of the SNc and 
the SNr.   
The striatum contains multiple types of neurons, including GABAergic and 
cholinergic neurons; however, it completely lacks glutamatergic neurons (Kreitzer et al., 
2008). The principal cell type in all the striatal regions is the GABAergic medium spiny 
neurons which constitute > 90% of all neurons in the striatum (Gerfen, 2004). These 
GABAergic medium spiny neurons are characterized by high spine density, negative 
resting potential, and low firing rates in vivo (Kreitzer et al., 2008).  Regulation of DA 
signaling in the striatum through GABAergic interneurons, along with the rest of basal 
ganglia, plays a crucial role in controlling motor coordination. 
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Figure 3: Tyrosine hydroxylase (TH, green) and dopamine transporter (DAT, red) 
immunostaining of dopamine projections in the striatum 
Twenty-five µm coronal rat brain section through striatum was immunostained for TH 
(green) and DAT (red) protein using primary TH (Millipore, Cat. No. MAB318, Mouse 
source, 1:1000) and DAT (Millipore, Cat. No. MAB369, Rabbit source, 1:1000) 
antibodies followed by detection using secondary infrared antibodies, goat anti-rabbit 680 
(Licor biosciences, Cat. No. 926-68021, 1:10,000) and goat anti-mouse (Licor 
biosciences, Cat. No. 926-32210, 1:10,000), respectively. Section was scanned on 
Odyssey scanner (Licor Biosciences). Sections prepared and stained by Mayur S. Parmar. 
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1.3 Development of dopaminergic system 
 
Midbrain dopaminergic (mDA) neurons are the main source of DA in the 
mammalian central nervous system and are located in three distinct nuclei: the ventral 
tegmental area (VTA), the substantia nigra pars compacta (SNc), and the retrorubral field 
(RrF; Prakash and Wurst, 2006). Cells of the SNc are involved in the control of voluntary 
movements and postural reflexes, and their degeneration in the adult brain has been 
associated with the development of Parkinson’s disease (PD; Fearnley and Lees, 1991; 
Anglade et al., 1997). Dopamine cells of the VTA modulate rewarding and cognitive 
behaviors, and dysregulation of DA transmission in the mesolimbic system has been 
implicated in the pathogenesis of addictive disorders (Kelley and Berridge, 2002; 
Wightman and Robinson, 2002), depression (Dailly et al., 2004), and the psychotic 
symptoms of schizophrenia (Carlsson et al., 2001; Sesack and Carr, 2002).  
During prenatal development, DA neurons are induced in the ventral midbrain by 
an interaction between two diffusible factors: sonic hedgehog (Shh) and fibroblast growth 
factor 8 (Fgf8; Simon et al., 2003). In mice, the first postmitotic differentiating DA 
neuron appears at embryonic day 10-10.5 (E10-10.5) during CNS development. By 
E11.5, the first specific sign of developing midbrain DA neurons, indicated by an 
increase in tyrosine hydroxylase (TH) expression, is observed (Foster et al., 1988; Wallen 
et al., 1999). The neurons of the SNc and RrF are generated first between E10 and E13 
(peaking at E11 and E12), whereas the neurons of the VTA are generated approximately 
1 day later, between E10 and E14 (peaking at E12 and E13) (Prakash and Wurst, 2006). 
Once DA neurons are generated, several transcription factors, which are crucial for 
postmitotic DA cell development, such as Nurr1, Lmx1b, Pitx3, and En1/En2, are 
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induced (Wallen and Perlmann, 2003). During prenatal development, DA neurons 
undergo generation, specification, and migration to their final positions. Midbrain VTA 
and SN neurons project via the medial forebrain bundle (MFB), arriving in the ventral 
and lateral regions of the rat STR at E14 and in the remaining areas of the STR by E18 
(Sillivan and Konradi, 2011). By E20, DA neurons assume topography similar to that of 
the adult brain (Shults et al., 1990).  
Following embryonic mitosis, specification, and migration, the events that occur 
during postnatal development of the dopaminergic system include establishment of 
contact and interaction between the SN and other neural nuclei; these developmental 
events occur through the extension of axons, terminal differentiation, and synaptic 
formation. A rapid increase in synaptic formation in the STR is observed between PND13 
and PND17 (Hattori and McGeer 1973), while postnatal differentiation of DA terminals 
is indicated by a large increase in STR TH activity and DA uptake between birth and 
PND30 (Coyle et al., 1977). A large increase in synapse formation is also observed in the 
SNc between PND15 and PND30.  Interestingly, a natural DA cell death event that is 
apoptotic and biphasic in nature is observed during postnatal development and is a 
common feature in mammals (Janec and Burke 1993; Oo and Burke 1997; Jackson-Lewis 
et al. 2000; Burke, 2003; Burke, 2004). For example, in rats, natural cell death (NCD) of 
DA neurons in the SNc begins shortly before birth and initially peaks on PND2 with a 
second, smaller peak at PND14 (Burke, 2003). By PND20, the event has largely abated 
(Burke, 2003). A natural cell death event is also observed in the STR between PND4 and 
8 (Fentress et al., 1981).  
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The sequence of events and the relative duration of mDA neuron development are 
conserved between mice and rats, taking into consideration that mouse development 
precedes that of rats by approximately 1 to 2 days (Prakash and Wurst, 2006). By the 
third postnatal week, the aspect of mDA neuron development (maturation of the mDA 
system) appears to be finished and the mDA system has acquired its adult morphology 
and functionality (Prakash and Wurst, 2006). These early brain development events 
ultimately determine brain function throughout life. 
1.3.1 Modulation of cellular signaling during development of the dopaminergic 
system 
Despite considerable progress in our understanding of the postnatal development 
of DA neurons in the vertebrate brain, including the determination of neuron number, 
axon guidance, target contact, and natural cell death events (Janec and Burke 1993; Oo 
and Burke 1997), cell signaling cascades within mesencephalic dopamine neurons that 
might alter and control these processes are not well studied and much remains to be 
elucidated. During early postnatal development of the dopaminergic system, any event 
that may alter the cellular signaling pathways required for normal growth could 
predispose an adult to the risk of developing neurodegenerative and neuropsychiatric 
disorders early or later in life, and/or alter the normal age-related changes in the 
dopaminergic system. Research has indicated that neurotoxin exposure during early brain 
development (prenatal or postnatal) has a profound, deleterious effect on the developing 
and adult nigrostriatal and mesocorticolimbic systems and leads to enhanced neuronal 
vulnerability, neurobehavioral impairments, and neurochemical alterations in the brain 
(Ling et al., 2002, 2004, 2006, 2009; Cory-Slechta et al., 2005a, 2005b; Richardson et al., 
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2006; Zhu et al., 2007; Olczak et al., 2011), which persist into adult life. Studies have 
also revealed that exposure to neurotoxins during development alter gene/protein 
expression in the adult offspring (Richardson et al., 2006, Schneider et al., 2011). As the 
dopaminergic system in the midbrain has been closely associated with serious 
neurodegenerative and neuropsychiatric disorders, the elucidation of the signaling 
mechanisms underlying dopaminergic neuronal development during the postnatal period 
becomes crucial for the understanding the development of disease state. 
1.4  Age-related changes in dopaminergic system  
1.4.1  Nigrostriatal system 
 
Advanced aging is associated with a progressive decline in motor functions due to 
dysfunctioning and degeneration of the nigrostriatal dopaminergic system (Emborg et al., 
1998; Seidler et al., 2010). Several investigators have reported neurochemical, 
neurophysiological, and cellular changes in the nigrostriatal dopaminergic system the 
brains of rodents, non-human primates, and humans during normal and diseased aging.  
With age, a reduction in the extracellular and tissue levels of DA in the SN and STR is 
observed (Carlsson & Winblad, 1976; Irwin et al. 1994; Gerhardt et al. 1995, 2002; Fox 
et al., 2001; Haycock et al., 2003). The age-related reduction of DA levels in the 
nigrostriatal system is associated with the progressive loss of TH
+
 DA neurons (McGeer 
et al., 1977; Fearnley and Lees, 1991; Emborg et al., 1998; Gerhardt et al., 2002) and/or a 
decrease in neuronal functioning due to a decline in TH mRNA, protein expression, and 
activity (McGeer et al., 1977; Dickerson et al., 2009). In addition to the loss of TH 
expression or activity, it has been reported that the loss of DA neurons in the SNc is 
approximately 0.5 to 0.7 % annually (Seidler et al., 2010).   
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Other normal age-related changes in the nigrostriatal system included the decline 
in expression of membrane DAT (Allard and Marcusson, 1989; Salvatore et al., 2003; 
Troiano et al., 2010), reductions in high affinity DA uptake sites (Zelnik et al., 1986; De 
Keyser et al., 1990; Yue et al., 2012), reduction in striatal DA uptake (Salvatore et al., 
2003; Yue et al., 2012), and decreases in dopamine D1 and/or D2 receptors (Henry et al., 
1986; Rinne et al., 1990; Volkow et al., 1996, 1998).  The decline in DAT and DAT 
mRNA appears to be high in the SN (Bannon et al., 1992; Bannon and Whitty, 1997; Ma 
et al., 1999) as compared to a stable or modest decline in the STR (Salvatore et al., 2003; 
Haycock et al., 2003). The age-related decline in DA transmission, TH
+
 neurons, TH 
expression, DAT, and DA receptors levels are strongly correlated with motor 
impairments, such as decreased locomotion, involuntary jerking arm movements, gait 
changes, and loss of balance during normal aging (Gerhardt et al., 1995, 2002; Emborg et 
al., 1998; Volkow et al., 1998; Cham et al., 2007, 2008; Salvatore et al., 2009; Seidler et 
al., 2010). However, a few groups have reported that there are no age-related changes in 
DA levels, TH
+
 DA neurons or DAT and TH protein expression levels in the nigrostriatal 
system (Wolf et al., 1991; Kubis et al., 2000; Salvatore et al., 2003; Allen et al., 2011). 
This variability might be associated with the methods of investigation and the animal 
strains used in the studies.  
Decrease in the levels of the neurotrophic factor receptors, GDNF receptor GDNF 
family receptor α-1 (GFRα-1) and the neuregulin receptor ErbB4, were observed in the 
nigrostriatal system with normal aging (Dickerson et al., 2009; Pruett and Salvatore, 
2010). Moreover, GDNF-mediated protection of DA neurons against 6-OHDA-induced 
toxicity was significantly lower in older animals as compared to young animals (Fox et 
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al., 2001).   These could be attributed to the lower levels of GFRα-1, resulting in 
reduction in activation of prosurvival signaling by GDNF. Increase in oxidative stress 
was also observed with aging in nigrostriatal system. A small, non-significant increase in 
the number of 3NT+ (3-nitrotyrosine; a marker of nitrative damage) neurons in the 
ventral SN was observed in old as compared to young animals (Kanaan et al., 2008). 
However, a significant increase in the percentage of TH
+
 neurons with 3NT was observed 
with age (Kanaan et al., 2008). With age, the increase in 3NT
+
/TH
+
 neurons was higher in 
ventral SN as compared to dorsal SN (Kanaan et al., 2008); a pattern indicating the 
greater vulnerability of ventral SN as compared to dorsal SN in PD.  
1.4.2 Mesoaccumbens system  
 
Unlike the nigrostriatal system, less information about age-related changes in the 
mesoaccumbens system (VTA and NAc) is available. Study by Siddiqi and colleagues 
(1999) reported age-related loss of total neurons in the paranigral nuclei of the VTA of 
the rhesus monkey. Salvatore and colleagues (2003) reported no age-related change in 
DAT protein levels in VTA and NAc. However, a decrease in TH protein expression was 
observed with age in the VTA (Salvatore et al., 2003). In contrast to TH protein levels, no 
change in TH mRNA levels was observed with age in the VTA by Dickerson and 
colleagues (2009). Contrary to reports of no change in DAT protein levels in the VTA 
and NAc with age (Salvatore et al., 2003), a reduction in DAT ligand binding with aging 
was observed in both VTA and NAc in the same rat strain by others (Hebert et al., 1999). 
Moreover, a modest decline in the DAT immunofluorescence was observed with age in 
the VTA (Kanaan et al., 2008).  This indicates that the age-related change in cellular 
localization of DAT might be important to study along with total DAT protein. Finally, a 
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decrease in the ratio of DAT/VMAT was observed in the VTA with age, indicating 
decreased capacity of DA neurons to accumulate cytosolic DA (Kanaan et al., 2008).  
1.5 Neurotrophic and neuropeptide therapies for dysfunctional dopaminergic 
system 
Neurotrophic factors, such as brain derived neurotrophic factor (BDNF), glial 
cell-derived neurotrophic factor (GDNF), and basic fibroblast growth factor (bFGF) have 
been shown to promote dopaminergic system development through differentiation of DA 
neuron precursors, maintaining DA neuronal viability and regulating early postnatal 
developmental cell death of dopamine neurons of the SN (Hyman et al., 1991; Burke, 
2003; Krieglstein, 2004; Oo et al, 2009). Moreover, these growth factors have been 
shown to provide protection of dopaminergic neurons and dopaminergic cells against 
neurotoxin-induced toxicity (Spina et al., 1992; Ugarte et al., 2003; Li et al., 2013; Hsuan 
et al., 2006). 
Among these growth factors, the high potency of GDNF in promoting dopamine 
neuronal survival, regeneration, and neuritic outgrowth (Lin et al., 1993; Zawada et al., 
1996; Deierborg et al., 2008) has made it the most widely studied neurotrophic factor as a 
therapeutic agent to treat neurodegenerative diseases, such as PD.  
1.5.1 Glial cell line-derived neurotrophic factor (GDNF) 
 
GDNF, a member of the transforming growth factor-β superfamily, was originally 
purified in 1993 from the rat glioma cell-line (B49) as a trophic factor that prompted the 
survival of embryonic dopaminergic neurons (Lin et al., 1993). At this time Lin and 
colleagues also noted that GDNF promotes dopamine uptake and increases TH
+
 DA 
neuron survival in midbrain cultures (Lin et al., 1993). In these cultures, GDNF affects 
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neither the density of astrocytes nor the expression of glial fibrillary acidic protein 
(GFAP), indicating its specificity and potency towards DA neurons (Lin et al., 1993). 
These effects of GDNF have also been confirmed in intact adult animals (Hudson et al., 
1995). A single intracranial, unilateral infusion of GDNF into the SN leads to a dose-
dependent and persistent increase in TH activity, DA levels, and DA turnover, both in the 
SN and STR (Hudson et al., 1995). No effect of GDNF infusion was observed on 
norepinephrine or serotonin levels (Hudson et al., 1995). In the same animals, increases 
in motor activity were observed following GDNF treatment (Hudson et al., 1995). In the 
STR, potassium and d-amphetamine-evoked DA release was increased in animals treated 
with GDNF (Hebert and Gerhardt, 1997). These promising effects of GDNF prompted 
studies to evaluate the ability of GDNF to protect dopamine neurons in vivo and in vitro 
against neurotoxins including MPTP, 6-OHDA, rotenone, and paraquat, all of which are 
known to induce specific DA neuronal loss. 
Using in vitro (Hou et al., 1996; Ugarte et al., 2003; Ding et al., 2004; Hsuan et 
al., 2006; Li et al, 2013) and in vivo rodent models (Hoffer et al., 1994; Kearns and Gash, 
1995; Connor et al., 2001, Fox et al., 2001) of dopaminergic dysfunction, several studies 
have demonstrated the potential of GDNF to protect DA neurons or dopaminergic cells 
against toxic insults and to enhance and/or partially restore dopaminergic neuronal 
function. In normal and parkinsonian, non-human primate models, GDNF treatment has 
led to significant improvements in neurochemical and behavioral function (Gash et al., 
1995, 1996; Zhang et al., 1997; Grondin et al., 2002). Improvements in neurochemical 
functions include an increase in DA and HVA levels in the nigrostriatal and 
mesoaccumbens pathways. Behavioral functions that improved following GDNF 
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treatment include alleviation in parkinsonism features, such as bradykinesia, rigidity, 
poor posture, and impaired balance. In the dopaminergic dysfunction/parkinsonian non-
human primate model, restoration of the nigrostriatal dopaminergic system and increases 
in both TH
+
 dopamine neurons and TH
+
 fiber density were also noted (Gash et al., 1995, 
1996, 2005; Grondin et al., 2002).  
Promising therapeutic results in the dopaminergic dysfunction/parkinsonian 
rodent and non-human primate model resulted in consideration of GDNF for clinical trial. 
In two different phase I clinical trials, GDNF therapy showed positive behavioral results 
including: 1) a 39% improvement in the off-medication motor score of the Unified 
Parkinson's Disease Rating Scale (UPDRS), 2) a 61% improvement in the activities of 
daily living score, 3) a 34% and 33% increase in total UPDRS score in “on” and “off” 
states, respectively, as compared to baseline after 24 weeks, 4) a 28% increase in 
putamen dopamine storage after 18 months of GDNF delivery, 5) improved balance and 
gait and increased speed of hand movements, which continued through the washout 
period, and 6) an improvement in fine motor control (Gill et al., 2003; Slevin et al., 
2005). However, in phase II, all clinical trials with GDNF were discontinued due to a 
lack of positive clinical results, detection of antibodies against GDNF in 10% of the 
patients undergoing trial, and observations of unusual cerebellar cortical pathology in 
non-human primates (Nutt et al., 2003; Land et al., 2006; Hovland et al., 2007). It is 
believed that technical differences in drug-delivery, thereby affecting distribution of 
GDNF, and inter-trial variability between both phases led to the discrepancies between 
results (Salvatore et al., 2006).  Due to the beneficial effects of GDNF on the 
dopaminergic system, as noted in rodents, non-human primates, and humans (phase I 
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clinical trial), numerous ongoing studies are focused on understanding the 
neuroprotective molecular mechanisms of GDNF. Studies are also focused on examining 
different GDNF formulations (Shingo et al., 2002) or routes of administration in order to 
avoid the issues raised during clinical trials. Despite the setbacks, GDNF remains a 
promising neurotrophic factor to halt the loss of dopamine neurons and restore normal 
dopaminergic system function in PD. 
1.5.1.1  Molecular mechanism of GDNF action 
 
GDNF signals through binding to its co-receptor complex, which consists of the 
GDNF family receptor, GFRα-1, and the membrane receptor, RET protein tyrosine 
kinase (RET). The mRNA and protein for these receptor components are present within 
the nigrostriatal and messoaccumbens pathways (Trupp et al., 1996; Golden et al., 1999; 
Smith et al., 2003; Pruett and Salvatore, 2010). Upon binding to its receptor complex, 
GDNF activates the PI-3K/Akt and mitogen-activated protein kinase (MAPKs) signal 
transduction pathways (Worby et al., 1996; Lindgren et al., 2008; Li et al., 2013). 
Activation of these signaling pathways by GDNF is known to protect dopaminergic 
MN9D cells against 6-OHDA-induced toxicity (Ugarte et al., 2003; Li et al., 2013). 
Protection of dopaminergic cells with GDNF is also mediated through activation of the 
NF-κB signaling pathway (Cao et al., 2008, 2013). GDNF-mediated upregulation of the 
anti-apoptotic proteins, Bcl (B-cell lymphoma) -2 and Bcl-w, and downregulation of the 
pro-apoptotic proteins, Bax and Bad, also resulted in MN9D cell protection against 6-
OHDA toxicity (Cao et al., 2013). Similarly, a study by Li et al. (2013) reported that 
GDNF-mediated upregulation of apoptosis-inhibiting genes (e.g. Ager), and 
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downregulation of apoptosis-promoting genes (e.g. Ccnl2) resulted in protection against 
6-OHDA toxicity in MN9D cells. 
1.5.2  Dopamine Neuron Stimulating Peptide-11 (DNSP-11) 
 
Due to CNS delivery issues with GDNF therapy, the search began for a small 
molecule that has potent neurotrophic effects, similar to GDNF, in terms of protecting the 
dopaminergic system and that can be easily delivered through alternative routes. 
Recently, a study by Bradley and colleagues (2010), reported an 11-mer peptide from the 
pro-GDNF domain called Dopamine Neuron Stimulating Peptide-11 (DNSP-11); in 
dopamine neurons, DNSP-11 displays both neurotropic and neuroprotective effects 
similar to GDNF (Fuqua, 2010; Sonne, 2013). Most importantly, they were able to 
deliver DNSP-11 through non-invasive intranasal administration and shown that it 
protects dopamine neurons against neurotoxin-mediated loss of dopamine neurons 
(Sonne et al., 2013). This indicates easy delivery of DNSP-11, thereby, presumably 
avoiding issues related to CNS route of administration. 
In vivo expression of DNSP-11 in rats was observed in the SN and VTA, and co-
localization of DNSP-11 was observed with TH
+
 DA neurons (Bradley et al., 2010). 
Further, when exogenous DNSP-11 was infused into the SN, it was rapidly and 
specifically taken up by the TH
+
 DA neurons (Bradley et al., 2010). Immunostaining for 
DNSP-11 also suggested its presence in other brain regions, such as the locus coeruleus 
(LC), glomeruli of the olfactory bulb, and dentate gyrus and CA1-CA3 regions of the 
hippocampus (Sonne, 2013). When dual-fluorescence immunohistochemistry was 
applied, colocalization of DNSP-11 and GDNF were observed in the adult facila motor 
nucleus, STR, cerebellum, and medial lemniscus (Sonne, 2013). Differences in the 
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localization of DNSP-11 and GDNF have also been observed in the SN, VTA, and LC 
regions (Sonne, 2013). Another important difference observed using 
immunohistochemistry was the presence of DNSP-11 during both postnatal development 
and adulthood in the SN, while GDNF was present only during postnatal development 
but dissipated in adulthood (Sonne, 2013). The expression differences of DNSP-11 and 
GDNF in various brain regions suggests that DNSP-11 and GDNF may be undergoing 
different post-translation modifications or may have different half-lives (Sonne, 2013). 
In an in vitro study of primary mesencephalic cells, DNSP-11 treatment increased 
cell survival comparable to results obtained following GDNF exposure (Bradley et al., 
2010). DNSP-11 treatment produced similar effects as GDNF treatment in enhancing 
morphological changes, such as neurite length and total branch number per neuron. 
Moreover, both DNSP-11 and GDNF treatment led to an increase in the total number of 
TH
+
 cells (Bradley et al., 2010). Also comparable to GDNF, DNSP-11 pretreatment 
reduced a 6-OHDA-induced increase in TUNEL positive staining, caspase-3 activity in 
the MN9D dopaminergic cell line (Bradley et al., 2010). DNSP-11 treatment also 
protected dopaminergic cell lines (MN9D and B65) against several other neurotoxins, 
such as rotenone and MPP+ (Bradley et al., 2013). Interestingly, unlike GDNF, DNSP-11 
protected the B65 cell line against staurosporine and gramicidin toxicity (Bradley et al., 
2010), suggesting a difference in the mechanisms of cellular protection. DNSP-11 has 
also been shown to protect cells against toxin-induced loss of mitochondrial membrane 
potential (Kelps et al., 2011; Bradley et al., 2013), indicating its mitochondrial-protective 
properties. DNSP-11 pretreatment blocked toxin-induced cytochrome c release from 
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mitochondria (Bradley et al., 2013) suggesting DNSP-11 may exploit apoptotic 
mechanisms at several points in the apoptotic pathway. 
In animal models, DNSP-11 appears to be comparable to GDNF in terms of its 
neuroprotective effect on the dopaminergic system. Infusion of DNSP-11 in the SN of 
normal rats resulted in an increase in baseline concentrations of DA and its metabolites, 
DOPAC and HVA, in the STR (Bradley et al., 2010). Intranasal delivery of DNSP-11 in 
normal rats significantly increased DA turnover [(DOPAC+HVA)/DA] in the STR and 
SN, and DA metabolites (DOPAC and HVA) in the SN (Sonne, 2013). In a rat model, 
one week after the induction of a 6-OHDA-induced lesion, post-infusion of DNSP-11 
reduced apomorphine-induced rotation behavior and increased DA and DOPAC levels in 
the SN (Bradley et al., 2010). Promising results were also observed with intranasal 
delivery of DNSP-11 in rats following 6-OHDA-induced lesions (Sonne, 2013). The 
beneficial neuroprotective properties of DNSP-11, combined with the ease of its 
intranasal delivery, make it a promising therapeutic agent to treat the dysfunctional 
dopaminergic system in PD. 
1.5.2.1  Molecular mechanism of DNSP-11 action 
 
Unlike GDNF, the neuroprotective molecular mechanisms of DNSP-11 are not 
well-established. However, similar to GDNF, DNSP-11 has been shown to activate 
ERK1 and ERK2 signaling (Bradley et al., 2013). However, it has not yet been elucidated 
whether DNSP-11-mediated activation of ERK1 and ERK2 or ERK5 are responsible for 
its neuroprotective properties.  MALDI-TOF mass spectroscopy indicated 16 cytosolic 
proteins pull-down by DNSP-11, out of which 11 possesses metabolic functions that 
includes a neuroprotective drug target, glyceraldehyde 3 Phosphate Dehydrogenase 
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(Bradley et al., 2010). This indicates that DNSP-11 might have neuroprotective properties 
due to its interaction with cytosolic proteins. 
1.6 Mitogen-activated protein kinase (MAPK) signaling 
Mitogen-activate protein kinases (MAPKs) are highly conserved enzymes that are 
involved in a multitude of cellular functions such as cell proliferation, differentiation, 
survival, and apoptosis (Cobb, 1999; Qi and Elion, 2005; Zhuang and Schnellmann, 
2006). Each MAPK cascade consists of a three-tier kinase cascade: a MAP kinase kinase 
kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK, MAP2K, or MEK), and 
a MAP kinase (MAPK). Sequential activation of MAPK kinases occur in response to 
either extracellular stimulation by growth factors or environmental stresses, finally 
resulting in MAPK phosphorylation. Specific downstream effector molecules 
(transcription factors, structural proteins, and cytoplasmic enzymes) are activated through 
sequential activation of each component of the MAPK cascade (Fig. 4) (Yang et al., 
2003; Qi and Elion, 2005; Yoon and Seger, 2006).  
MAPKs are activated by dual phosphorylation of conserved threonine and 
tyrosine residues within the activation loop of the kinase (denoted T-X-Y) and the MAPK 
targets contain a Pro-Xxx-Ser/Thr-Pro sequence (Ferrell and Bhatt, 1997; Pearson et al., 
2001; Qi and Elion, 2005; Nithianandarajah et al., 2012). Once activated, MAPKs can 
translocate from the cytoplasm to the nucleus to phosphorylate nuclear targets, and once 
dephosphorylated they translocate from the nucleus back to the cytoplasm (Kondoh et al., 
2006; Nithianandarajah et al., 2012). The activated MAPKs can remain in the cytoplasm 
and activate cytoplasmic proteins (Bondi et al., 2008). The activation of MAPK is 
terminated by a group of dual-specificity MAPK phosphatases, known as DUSPs or 
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MKPs, tyrosine phosphatases and serine/threonine phosphatases that can act upon 
tyrosine and serine/threonine residues (Zheng and Guan, 1993; Keyse, 2000). Blocking 
these phosphatases leads to prolonged MAPK activation. 
At least four members of the MAPK family have been identified: extracellular-
signal-regulated kinases 1 and 2 (ERK1/2), ERK5, c-Jun-amino-terminal kinase (JNK), 
and p38 (Fig. 4; Nishida and Gotoh, 1993; Robinson and Cobb, 1997; Cavanaugh, 2004; 
Nithianandarajah et al., 2012). Among these four MAPK pathways, ERK1/2 and ERK5 
MAPKs are activated by growth factors and hormones, while the remaining two, JNK 
and p38 MAPKs are activated in response to cellular stress. 
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Figure 4: Mitogen-activated protein kinase (MAPK) signaling 
There are four major mammalian MAPK subfamilies: ERK1/2, ERK5, p38, and JNK. A 
MAP Kinase Kinase Kinase (MAPKKK) phosphorylates and activates a MAP Kinase 
Kinase (MAPKK), and then MAPKK phosphorylates and activates a MAP Kinase 
(MAPK). GPCRs - G-protein-coupled receptors, IL-β – Interleukin-beta, UV – 
Ultraviolet  irradiation, CREB - cAMP response element binding protein, MEF2C - 
Myocyte enhancer factor 2C, MEF2A - Myocyte enhancer factor 2A, Serum- and 
glucocorticoid-regulated protein kinase – SGK, p90 ribosomal S6 kinase - p90RSK. 
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1.6.1 ERK1 and ERK2 (Referred to as ERK1/2) 
 
ERK1 and 2 activation is important for a multitude of functions, including cell 
proliferation, differentiation, cell survival, and cell death events (Chen et al., 2001) These 
two ERK isoforms, ERK1 (44 kDa) and 2 (42 kDa) are 84% homologous in amino acid 
sequence and activate the same downstream substrates due to similar substrate 
recognition properties and subcellular localization (Segers and Krebs, 1995). They are 
shown to be activated by the same cellular stimulants leading to parallel activation of 
ERK1 and ERK2. Interestingly, the activation ratio of ERK1/ERK2 in cells corresponds 
to their expression ratio, indicating their parallel activation profile (Lefloch et al., 2008). 
It is assumed that ERK1 and ERK2 functions are equivalent; however, recent studies 
have elucidated functional differences between the kinases (Vantaggiato et al., 2006; 
Marchi et al., 2008; Roskoski, 2012).  For example, knockdown of erk2 in mice has 
shown to be embryonic lethal (Yao et al., 2003; Hatano et al., 2003; Saba-El-Leil et al., 
2003), while erk1 is dispensable for the development of mice. Knockdown of erk1 only 
caused deficits in tymocyte maturation and subtle alterations in synaptic plasticity and 
behavior, with no effect on viability, fertility, or body size (Pages et al., 1999; 
Mazzucchelli et al., 2002; Nekrasova et al., 2005).  Furthermore, in neuronal-like NIH 
3T3 cells, erk1 knockdown has been shown to facilitate growth, while erk2 knockdown 
inhibited the growth (Vantaggiato et al., 2006).  
ERK1 and ERK2 are activated by MEK1 and MEK2, which belong to the 
MAPKK family. The activation of MEK1 and MEK2 is via MAPKKK-mediated 
phosphorylation, which includes members of the Raf family, as well as Mos and 
Tpl2/Cot. Raf activators include small GTPases, Ras or Rap3. MEK1 and 2-mediated 
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phosphorylation of ERK1 and 2 occurs on threonine and tyrosine residues (T-E-Y). 
MEK1 and MEK2 activate ERK1 and ERK2 through phosphorylation of activation loop 
residues Thr
202
/Tyr
204
 and Thr
185
/Tyr
187
, respectively. Once phosphorylated, ERK1 and 2 
(Fig. 5) translocate into the nucleus where it activates nuclear transcription targets, such 
as Elk1, cAMP response element binding protein (CREB), c-Myc, c-Fos and protein 
kinases, such as p90 ribosomal S6 kinase (p90RSK), to induce gene expression (Yu et al., 
2001; Hu et al., 2004; Cavanaugh et al., 2006) or remain in the cytoplasm and activate 
cytosolic proteins (Bondi et al., 2008). The rate of translocation of ERK1 and ERK2 
depends on the phosphorylation status (Fujioka et al., 2006; Marchi et al., 2008). Marchi 
and colleagues (2008) observed that ERK1 shuttles between the nucleus and cytoplasm at 
a much slower rate than ERK2 and this functional difference is associated with the N-
terminal domain of ERK1. Furthermore, differences in the ability of ERK1 and ERK2 to 
interact with the upstream MEK activator and nucleocytoplasmic trafficking have been 
noted (Vantaggiato et al., 2006; Marchi et al., 2008) that could result in lower signaling 
output of ERK1 as compared to ERK2. 
33 
 
 
Figure 5:  ERK1 and ERK2 cytoplasmic and nuclear localization 
 
ERK1/2 does not contain nuclear localization signal (NLS) and nuclear export signal 
(NES) domain. However, an NES domain is found on MEK1/2 (Fukuda et al, 1996), 
which is bound to ERK1/2 when MEK1/2 and ERK1/2 are not phosphorylated. This NES 
domain target MEK 1/2 to the cytoplasm (Kolch, 2005), thereby, the MEK1/2 / ERK1/2 
complex. Therefore, MEK1/2 retains ERK1/2 in the cytoplasm through direct interaction 
(Fukuda et al, 1996). Following activation of MEK1/2, ERK1/2 is phosphorylated, 
dissociates from MEK1/2, and translocate to the nucleus. Once ERK1/2 gets 
dephosphorylated in nucleus by phosphatases, the ERK1/2 binds to the MEK1/2 that has 
entered into nucleus through passive diffusion (Adachi et al, 2000; Yao et al, 2001). This 
complex is then exported out of nucleus.  
Adapted from Nishimoto, S., Nishida, E., 2006. MAPK signalling: ERK5 versus ERK1/2. 
EMBO Rep. 7, 782-786. 
 
 
 
 
The inactivation/de-phosphorylation of ERK1 and ERK2 is carried out by 
tyrosine, serine/threonine, or both tyrosine and threonine (dual-specificity) MAPK 
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phosphates, known as DUSPs or MKPs (Owens and Keyse, 2007; Roskoski, 2012).  The 
tyrosine-specific MKPs include protein tyrosine phosphatases-SL (PTP-SL), striatal-
enriched PTP (STEP), and hematopoietic specific cytoplasmic PTP (HePTP), whereas the 
serine/threonine-specific MKPs include protein phosphatase 2A and 2CA (Roskoski, 
2012). A single removal of two phosphates on the activated ERK2 has shown to 
inactivate the kinase (Anderson et al., 1990). Among DUSPs, three closely related 
cytoplasmic phosphatases DUSP6/MKP-3, DUSP7/MKP-X and DUSP9/MKP-4 have 
shown preferentially to inactivate ERK1 and ERK2 (Owens and Keyse, 2007).  
1.6.1.1 Neuronal roles of ERK1 and ERK2 in vitro and in vivo  
 
In the nervous system, ERK1 and 2 have been shown to play roles in several 
biological processes, including neuronal differentiation, memory formation, plasticity, 
and neuronal survival (Adams et al., 2002; Hetman and Gozdz, 2004). Among several 
pro-survival signaling molecules, ERK1 and ERK2 has been shown to play a 
neuroprotective role in wide range of neurons or neuronal cells (Xia et al., 1995; 
Cavanaugh et al., 2006; Hsuan et al., 2006; Gu et al., 2009).  Many neuroprotective 
agents, such as luteolin (Wruck et al., 2007), GDNF (Ugarte et al., 2003), and bFGF 
(Hsuan et al., 2006) have shown to protect neurons or neuronal cells against MPTP, 6-
OHDA, or rotenone-induced neurotoxicity through activation of ERK1 and 2. In 
dopaminergic MN9D cells, activation of ERK1and 2 haves also shown to promote basal 
survival and cell survival following exposure to oxidative stress stimuli (Cavanaugh et 
al., 2006; Gu et al., 2009). Numerous in vivo studies have also indicated roles for ERK1 
and 2 in neuronal protection. For example, a study by Troadec and colleagues (2002) 
reported that activation of the ERK1 and ERK2 signaling by cyclic AMP potentiated the 
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neuroprotective effect of noradrenaline on dopamine neurons. Additionally, Pernet and 
colleagues (2005) observed that ERK1 and 2 is important for the regulation of adult RGC 
survival, in vivo, after traumatic injury. 
The neuroprotective properties of ERK1and ERK2 have been associated with the 
anti-apoptotic properties of these kinases, which include phosphorylation and subsequent 
inactivation of pro-apoptotic members of the Bcl-2 family of proteins, Bim and BAD 
(Hetman et al., 2004; Hsuan et al., 2006). Neuroprotection by ERK1 and 2 may also be 
due to increases in expression of anti-apoptotic proteins, such as Bcl-xL and Bcl-2, 
following activation of CREB by ERK1 and 2 (Hetman et al., 2004; Creson et al., 2009). 
Neurotrophic and neurotrophin factors that are important for the survival of 
neurons, such as GDNF, BDNF, and bFGF, have been shown to activate ERK1 and 2 
signaling (Hetman et al., 1999; Cavanaugh et al., 2001; Coulpier and Ibanez, 2004; 
Hsuan et al., 2006; Lindgren et al., 2012). Moreover, transcription of and release of these 
growth factors from astrocytes or neurons under normal conditions, in response to stress 
or stimulation occurs following activation of ERK1 and 2 signaling (Su et al., 2011; Di 
Benedetto et al., 2012). 
1.6.1.2 The Role of ERK1 and ERK2 in Apoptosis 
 
Although activation of ERK1 and 2 is generally associated with neuronal 
protection, these kinases have also been shown to play a role in promoting neuronal cell 
death in oxidative stress models both in vitro (Jiang et al., 2000; Kulich and Chu, 2001; 
Lesuisse and Martin, 2002; Gomez-Santos et al., 2002; Subramaniam et al., 2003, 2004) 
and in vivo (Alessandrini et al., 1999; Namura et al., 2001; Wang et al., 2003). The 
proapoptotic roles of ERK1 and ERK2 depend upon the cell type, the stimulus, and the 
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duration of activation (Zhuang and Schnellmann, 2006). The intrinsic and extrinsic 
pathways involved in ERK1 and ERK2-mediated apoptosis, include depolarization of the 
mitochondria membrane, induction of expression of the proapoptotic protein p53, release 
of cytochrome c, and activation of caspase-3 or caspase-8 (Zhuang and Schnellmann, 
2006).  
1.6.2 ERK5 
 
Extracellular-signal-regulated kinase 5 (ERK5, 814 amino-acids, 125 kDa) is a 
new member of the mitogen-activated protein kinase (MAPK) family and similar to 
ERK1 and 2 contains the Thr–Glu–Tyr (TEY) activation motif (Fig. 6). Also similar to 
ERK1 and ERK2, ERK5 is activated by growth factors and has been shown to play an 
important role in numerous cellular processes including regulation of cell proliferation, 
differentiation, neurogenesis, and neuronal survival (Watson et al., 2001; Hayashi and 
Lee, 2004; Cavanaugh, 2004; Wang and Tournier, 2006; Pan et al., 2012). Knockdown of 
the erk5 or mek5 gene has shown to be embryonic lethal due to multiple defects in 
cardiovascular, angiogenesis, and placental and embryonic development (Regan et al., 
2002; Yan et al., 2003; Wang et al., 2005). ERK5, also known as big MAP kinase 1 
(BMK1) and mitogen-activated protein kinase 7, is twice the size of other MAPKs (Lee 
et al, 1995; Zhou et al, 1995). In 1995, two groups Lee et al. (1995) and Zhou et al. 
(1995) simultaneously cloned ERK5. These were the first studies to note that ERK5 
contains the TEY activation motif and shares sequence homology with ERK1 and ERK2 
(Lee et al, 1995; Zhou et al, 1995). The kinase domain of ERK5 shares 66% sequence 
homology to the kinase domain of ERK2 (Zhou et al., 1995). The distinguishing 
structural feature of ERK5, as compared to ERK1 and ERK2, is the presence of a large 
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C-terminal (410 amino acids) and a unique loop-12 sequence (Lee et al, 1995; 
Nithianandarajah et al., 2012).  A nuclear localization signal (NLS) domain exists within 
the C-terminal domain, (Fig. 6). This NLS domain is important for ERK5 nuclear 
targeting (Buschbeck et al., 2005).  
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Figure 6: Structure of ERK5 and functional domains 
ERK5 consists of 816 amino acids (a.a.) residues. In the N-terminus, there is kinase 
domain that contains the MEK5 binding site.  In the C-terminal of ERK5, there are two 
proline rich domains (PR1 and PR2), nuclear localization signal (NLS), and nuclear 
export signal. NES is also present in the N-terminus.  
Image adapted from Nithianandarajah-Jones, G.N., Wilm, B., Goldring, C.E., Müller, J., 
Cross, M.J., 2012. ERK5: Structure, regulation and function. Cell.Signal. 
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Figure 7: ERK5 cytoplasmic and nuclear localization 
Nucleocytoplasmic shuttling of ERK5 is controlled by its own N-terminal half and C-
terminal half and these processes are phosphorylation-dependent control mechanism 
(Kondoh et al., 2006). ERK5 has nuclear localization signal (NLS) in its carboxy-
terminal region.  In the resting, non-phosphorylated state, both the N-terminal and C-
terminal produce a nuclear export signal (NES). The NES is recognized by cytoplasmic 
anchor proteins helping to retain ERK5 in the cytoplasm. Once phosphorylated by 
MEK5, the dissociation between the N- and C-terminal halves occur, resulting in a loss of 
NES activity, causing the nuclear import of ERK5.  
Image adapted from Nithianandarajah-Jones, G.N., Wilm, B., Goldring, C.E., Müller, J., 
Cross, M.J., 2012. ERK5: Structure, regulation and function. Cell.Signal. 
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ERK5 is activated directly by MEK5, a specific MAPKK for ERK5, in a growth 
factor-dependent, Ras-independent mechanism (Kato et al., 1997, 1998; Dong et al., 
2001). The activation of MEK5 is through MEKK2 and MEKK3, members of the 
MAPKKKs family (Chao et al., 1999; Sun et al., 2001). MEK5 activates ERK5 through 
dual phosphorylation of Thr
218
 and Tyr
220
 in the activation loop of the kinase domain 
(Mody et al., 2003) (Fig. 7). Further, activation of ERK5 leads to ERK5 
autophosphorylation in its unique C-terminal domain (Morimoto et al., 2007).  This 
phosphorylated ERK5 regulates gene expression through its C-terminal transcriptional 
activation domain (Morimoto et al., 2007). Once phosphorylated, ERK5 translocates into 
the nucleus where it activates nuclear myocyte enhancer factor 2 family members, such 
as MEF2C, and other transcription targets including c-Fos, Fos-related antigen-1(Fra-1), 
Serum- and Glucocorticoid-regulated protein Kinase (SGK) and Sap1a (Kato et al., 1997, 
1998; Kamakura et al., 1999; Hayashi et al., 2001; Terasawa et al., 2003). 
Nucleocytoplasmic shuttling of ERK5 is controlled by its own N-terminal half and C-
terminal half and these processes are phosphorylation-dependent mechanisms 
(Buschbeck et al., 2005; Kondoh et al., 2006).  Binding of the N- and C- terminal halves 
of ERK5 is important for nuclear export of ERK5, while phosphorylation of ERK5 by 
MEK5 results in the dissociation of the binding between the N- and C-terminal halves 
and thus inhibits nuclear export of ERK5. Unlike ERK1 and ERK2, the DUSPs or MKPs 
that dephosphorylate Thr
218
 and Tyr
220
 of ERK5 are not clearly identified.  
1.6.2.1  Neuronal roles of ERK5 in vitro and in vivo  
 
In the CNS and PNS, ERK5 has been indicated for several biological processes, 
including neuronal differentiation, migration, neurogenesis, neutrite outgrowth, 
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development, memory formation, and neuronal survival (Watson et al., 2001; Liu et al., 
2003, 2006; Cavanaugh, 2004; Cundiff et al., 2009; Obara et al., 2009; Pan et al., 2012; 
Zou et al., 2012; Li et al., 2013). Specifically, in response to diverse neurotrophic pro-
survival stimuli, ERK5 signaling has shown to be crucial for neuronal cell survival and 
development (Cavanaugh et al., 2001; Watson et al., 2001; Liu et al., 2003, 2006; Shalizi 
et al., 2003; Finegan et al., 2009). Activation of ERK5 signaling has been shown to be 
important for the regulating release of neurotrophic and neurotrophin factors, such as 
GDNF and BDNF, from astrocytes under normal conditions (Obara et al., 2011; Su et al., 
2011). 
A study by Liu et al. (2006) suggests that ERK5 is crucial for basal cortical 
neuronal survival during development. In this study, a decrease in ERK5 expression in 
embryonic cortical neurons (E17) resulted in a loss of BDNF-mediated neuroprotection 
from serum withdrawal. Furthermore, during the neurogenic period of cortical 
development, these investigators observed an increase in the expression of activated 
ERK5 (Liu et al., 2006). Furthermore, when E13 cortical progenitor cells were exposed 
to ciliary neurotrophic factor (CNTF), ERK5 expression was crucial for their 
neurogenesis (Liu et al., 2006). In a separate study, neurogenin 1-mediated cortical 
neurogenesis was also inhibited when ERK5 signaling was blocked (Cundiff et al., 2009). 
Similar to these studies in cortical neurons, a report by Shalizi and colleagues (2003) 
shows that inhibition of ERK5 signaling in immature cerebellar neurons resulted in a loss 
of BDNF-mediated neuroprotection from trophic factor withdrawal. 
  Numerous in vivo studies also have indicated a crucial role for ERK5 in 
neurogenesis, neuronal development, and survival (Zou et al., 2012; Li et al., 2013). 
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Higher expression of ERK5 has been observed during embryonic and postnatal 
development of the brain, specifically the cortex, as compared to expression in the mature 
brain (Liu et al., 2003, 2006). Conditional deletion of ERK5, specifically in the adult 
neurogenic regions, has been shown to delay the normal progression of neuronal 
differentiation and attenuation of adult neurogenesis in vivo (Pan et al., 2012; Wang et al., 
2013) 
Neuroprotective properties of ERK5 are associated with modulation of anti-
apoptotic and pro-apoptotic signaling proteins.  A study by Finegan et al. (2009) reported 
that ERK5 regulates apoptosis through inhibition of pro-apoptotic protein expression and 
transcription, including Bad, and Bim. 
1.6.2.2  The Role of ERK5 in Apoptosis 
 
So far, only one study has reported a role for ERK5 in the induction of apoptosis 
(Sturla et al., 2005). In two medulloblastoma cell lines and primary cultures of mouse 
medulloblastomas, overexpression of ERK5 increased apoptosis (Sturla et al., 2005). 
Also, when expression of MEK5 was inhibited using small interfering RNA, 
neurotrophin-3 induced apoptotis was blocked (Sturla et al., 2005). Moreover, 
overexpression of a dominant-negative mutant of MEF2, a specific downstream target of 
ERK5, resulted in inhibition of MEK5/ERK5-induced cell death (Sturla et al., 2005). 
1.6.3  MAPK signaling: ERK5 versus ERK1 and ERK2 
 
Structurally, ERK5 is twice the size of other MAPKs (Lee et al, 1995; Zhou et al, 
1995). The carboxyl-terminal half in ERK5 is unique as compared to ERK1 and ERK2, 
while the amino-terminal half that contains the kinase domain is similar to that of ERK1 
and ERK2. The upstream and downstream targets of ERK5, and ERK1 and 2 are 
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different. ERK5 is activated specifically by upstream components, such as Ras, MEKK2, 
MEKK3, and MEK5, while ERK1 and ERK2 are activated specifically by upstream 
components, such as Raf family members and MEK1 and 2. Downstream target of ERK5 
includes myocyte enhancer factor 2 family members, such as MEF2C and MEF2A (Kato 
et al., 1997, 1998; Cavanaugh et al., 2001), while ERK1 and 2 activates downstream 
target such as Elk1 (Hu et al., 2004). However there are common downstream targets of 
ERK1 and ERK2, and 5, such as the c-Myc, c-Fos, CREB and Sap1a transcription factors 
(Gille et al., 1992; Cavanaugh et al., 2006). 
1.7 Fisher 344 x Brown-Norway F1 rat: Animal model to study nigrostriatal 
system deficiency with aging  
The Fisher 344 x Brown-Norway F1 (F344xBN F1, a hybrid strain) is a widely 
used rat model to study age-related pathologies due to decreased variability in several 
physiological and behavioral measures (Phelan and Austad, 1994).  This strain displays 
advantages over other strains commonly used for aging studies, such as Fisher 344 
(F344), Brown-Norway (BN), and Sprague Dawley (SPD). Some of the advantages of the 
F344xBN F1 strain include: 1) age-related pathologies occur relatively late in life  
(Lushaj et al., 2008), thereby, decreasing the rate of mortality, 2) 50% mortality is 
attained at 146 weeks of age as compared to 103 and 130 week of age for F344 and BN, 
respectively (Lipman et al., 1996), 3) low incidence of renal pathology is observed as 
compared to aged Fisher 344 (Lipman et al., 1996), and 4) no specific tumor 
susceptibilities, known to occur in alternative rat models of aging, have been observed. 
With respect to the nigrostriatal system, the age-related changes in both the 
striatum and midbrain of F344xBN F1 rats are comparable to that observed in aging 
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primates and humans (Allard and Marcusson, 1989; Spangler et al., 1994; Yurek et al., 
1998; Troiano et al., 2010; Horner et al., 2011). These similarities allow for the study of 
age-related motor dysfunction and changes that occur in the dopaminergic system with 
normal aging. As compared to BN and F344, F344xBN F1 rats exhibit a greater reduction 
in locomotor activity with age (Spangler et al., 1994). Decreases in locomotor or motor 
performance, and lower levels of spontaneous and D-amphetamine-induced locomotor 
activity is observed in old F344XBN F1 rats as compared to young (Yurek et al., 1998; 
Salvatore et al., 2009; Horner et al., 2011). Further, in middle-aged and old F344xBN F1 
rats, fewer TH-IR neurons were observed in the substantia nigra and lower extracellular 
levels of DA, DOPAC, and HVA were detected in the striatum as compared to young 
animals (Yurek et al., 1998; Fox et al., 2001). Decreased tissue levels of DA were also 
observed in the ventral striatum and midbrain in the old-aged F344xBN F1 as compared 
to young rats (Yurek et al., 1998; Salvatore et al., 2009; Salvatore and Pruett, 2012). 
These age-related declines in DA neurochemistry are well correlated with diminished 
motor function in this aged animal model (Yurek et al., 1998). Levels of tyrosine-
hydroxylase proteins have also been found to decline with age in the striatum and 
substantia nigra of old F344xBN F1 rats (Salvatore et al., 2009;  Salvatore and Pruett, 
2012; Dickerson et al., 2009). A decline in DAT protein expression was also observed in 
this strain (chapter 2), similar to the decline in DAT levels observed with normal aging in 
primates and humans (Allard and Marcusson, 1989; Troiano et al., 2010). 
Neurotrophic factors such as GDNF and neuregulins have been shown to be 
important for the survival of dopaminergic neurons against neurotoxin-induced oxidative 
stress (Fox et al., 2001; Carlsson et al., 2011). With aging, a significant reduction in the 
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level of GDNF protein in the striatum and ventral midbrain has been observed in this 
strain (Yurek and Fletcher-Turner, 2001).  Expression levels of the neurotrophic factor 
receptors, GDNF receptor GDNF family receptor α-1 (GFRα-1) and the neuregulin 
receptor ErbB4, also significantly decrease with normal aging in the substantia nigra of 
F344xBN F1 rats (Dickerson et al., 2009; Pruett and Salvatore, 2010). The deficiency in 
the GDNF- GFRα-1 and NRG- ErbB4 mediated signaling with normal aging could be 
contributing to a decline in DA neurons and DA levels, thereby reducing locomotor 
activity. 
Overall, the comparable deficiency in the dopaminergic system of normal aging 
F344xBN F1 rats to that observed in primates makes them an appropriate model to study 
neurochemical, molecular, and cellular alterations in the aging nigrostriatal system as 
seen in human aging and early Parkinson's disease.  
1.8 6-Hydroxyamine 
 
6-hydroxyamine (6-OHDA) is a widely used neurotoxin for in vitro and in vivo 
studies to induce oxidative stress in the catecholaminergic neurons, especially dopamine 
neurons. It is a hydroxylated analogue of the dopamine neurotransmitter. Due to its some 
structural similarities with dopamine, it exhibits a high affinity for dopamine transporters 
(DAT) that are present on the plasma membrane of dopamine neurons. It is widely used 
to generate experimental models of dopamine lesions and motor impairments as observed 
in PD. It has been reported that 6-OHDA have been observed to be present in both rat 
(Senoh et al., 1959a, 1959b) and human brain (Curtius et al., 1974), including in urine of 
L-dopa treated PD patients (Andrew et al., 1993). 
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Several mechanisms have been involved in 6-OHDA induced cell death. Once it 
enters the cell, it gets easily oxidized to free radicals, such as hydrogen peroxide and 
hydroxyl radicals, thereby, inducing oxidative stress. The 6-OHDA induced-oxidative 
stress results in cascade of events that result in apoptosis. Such events includes: 1) 
Alterations in Bcl-2 family proteins (anti-apoptotic – Bcl-2, Bcl-2 and apoptotic – Bim) 
expression that are present on mitochondrial memebrane, thereby, controling 
mitochondrial outer membrane potential. 2) Disturbance of mitochondrial outer 
membrane potential, results in release of cytochrome c, which further result in caspase-
3/7 activation through series of cellular events. Caspases 3 and 7 are family of cystein 
proteases, which are key mediators of mitochondrial events of apoptosis. The activation 
of caspase-3/7 has been shown to induce apoptotic cell death through proteolysis of 
numerous cellular proteins. 3) Direct inhibition of mitochondrial respiratory chain, 
thereby, further increasing level of oxidative stress within cell. 4) 6-OHDA induced 
oxidative stress also results in increase in lipid peroxidation of plasma membrane, 
thereby, cytoskeleton disorganization. 5) Auto-oxidation of 6-OHDA outside the cell 
results in oxidative damage to plasma membrane, thereby, cell death. 
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Figure 8: Molecular pathways involved in the neurotoxicity of 6-OHDA 
6-OHDA – 6-hyroxydopamine; DAT – Dopamine transporter; H2O2 – Hydrogen 
peroxide; MAO - Monoamine oxidase. Image from Blum et al. 2001. 
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In summary, the objectives of these study were to determine 1) the age-related 
changes in the total (non-phosphorylated) and phosphorylated protein expression of 
ERK1, ERK2, and ERK5 in the dopaminergic regions, SN, STR, and VTA, 2) the role of 
ERK1, ERK2, and ERK5 in the basal survival of dopaminergic neurons from SN, and 
VTA, and 3) the neuroprotective properties of GDNF and DNSP-11 in human 
dopaminergic SH-SY5Y neuroblastoma cell-line. 
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Chapter 2: Role of ERK1/2 and ERK5 in dopamine neuronal survival 
 
2.1  Rationale 
 
Extracellular signal-regulated kinases (ERK) 1, 2, and 5 are members of the 
mitogen-activated protein kinase (MAPK) family that regulate many physiological 
processes during neurodevelopment, including apoptotic cell death and the maintenance 
of neuronal viability following oxidative insults (Xia et al., 1995; Liu et al., 2003; 2006; 
Cavanaugh, 2004; Watson et al., 2001; Satoh et al., 2011). Age-associated changes in 
ERK1 and ERK2 expression and activation have been observed, although the nature of 
these changes is controversial. For example, Song and colleagues (2007) reported an 
increase in phosphorylated ERK1 and 2 (p-ERK1 and p-ERK2, respectively) levels in the 
hippocampus, frontal cortex, and striatum in 24-month old animals. However, Mo and 
colleagues (2005) demonstrated a decrease in p-ERK1 and p-ERK2 levels in these same 
brain regions in 22-month old rats. Although ERK5 expression has not been studied in 
the aging brain, Liu and colleagues (2003; 2006) observed high levels of ERK5 in early 
embryonic stages that decreased in the whole brain and cortex of postnatal and adult 
Sprague-Dawley rats.  
 To date, no studies have been performed to examine the relative expression and 
activation of ERK1, ERK2, and ERK5 in dopaminergic regions of the brain with aging or 
their roles in the survival of dopamine (DA) neurons. Although ERK5 has been shown to 
be crucial for the basal survival of MN9D dopaminergic cells (Cavanaugh et al., 2006), 
its role in the survival of primary DA neurons has not been explored. In this study, we 
examined the expression and activation of ERK1, ERK2, and ERK5 in the SN, STR, and 
VTA during aging. Further, we examined the relative roles of these ERK isoforms in DA 
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neuronal survival. Due to the involvement of dopaminergic neuronal systems in 
Parkinson’s disease and other mental disorders, elucidation of cellular signaling 
alterations that may be responsible for the decrease in dopaminergic function with age 
may advance our understanding of neurological disorders and lead to the identification of 
novel drug targets for these conditions. 
2.2  Hypothesis  
 
With age, ERK5 expression and activation decreases, while ERK1/2 increases in 
dopaminergic brain regions.  
2.3 Materials and Methods 
2.3.1  Animals  
 
To determine ERK expression in the SN, STR, and VTA with age, young (3 mo.), 
middle-aged (13 mo.), and old (23 mo.) male Fisher 344 x Brown-Norway F1 hybrid 
(F344xBN F1) rats were obtained from the National Institute on Aging colonies (Harlan 
Sprague-Dawley, Indianapolis, IN). For primary neuronal cultures, timed pregnant 
Sprague-Dawley rats (Hilltop Laboratory Inc., Scottdale, PA) were used. Animals were 
single-housed in a 12:12 light: dark cycle and provided with water and rat chow ad 
libitum. All procedures were conducted in accordance with the guidelines for the NIH 
Care and Use of Laboratory Animals and approved by the Duquesne University or the 
University of Pittsburgh Institutional Animal Care and Use Committees. 
2.3.2  Materials and tissue preparation  
 
  For western blot analysis, tissue samples were sonicated in ice-cold 1:20 (w/v) 
homogenation lysis buffer (20 mM Tris, pH 6.8, 137 mM NaCl, 25 mM β-
glycerophosphate, pH 7.14, 2 mM NaPPi, 2 mM EDTA, 1 mM Na3VO4, 1% Triton X-
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100, 10% glycerol, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 2 mM benzamidine, 0.5 mM 
DTT and 1 mM PMSF) using a 2% pulse. Total homogenate was centrifuged at 11,000 
rpm for 30 min at 4 ºC and the supernatant was collected and stored at -80 ºC until 
analysis.  
2.3.3  Western blot analysis 
 
Total protein content was assessed by Bradford Bio-Rad protein assay (Cat. No. 
500-0006, Bio-Rad, Hercules, CA) and 60 μg of protein was loaded on an 8% SDS-
PAGE gel and transferred to a nitrocellulose membrane (Cat. No. 926-31092, Licor 
Biosciences, Lincoln, NE). After transfer, membranes were washed for 5 min with 1X 
PBS and blocked for 1 h in a casein blocking buffer (Cat. No. 927-40200, Licor 
Biosciences) at room temperature. Membranes were then incubated overnight at 4 ºC in 
primary antibody in casein blocking buffer with 0.1% Tween-20. Antibodies included 
rabbit anti-phospho-ERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling, Beverly, 
MA), mouse anti-total ERK1/2 (Dilution – 1:2000, Cat. No. 9107, Cell Signaling), rabbit 
anti-phospho-ERK5 (Dilution – 1:500, Cat. No. 3371, Cell Signaling) and rabbit anti-
total ERK5 (Dilution – 1:1,000, Cat. No. E1523, Sigma-Aldrich, St. Louis, MO). Mouse 
anti-α-Tubulin (Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a 
loading control. After incubation with primary antibody, blots were washed in 1X PBS 
solution with 0.1% Tween-20 (1X PBS-T) and incubated with goat anti-rabbit (Dilution – 
1:20,000, Cat. No. 926-68021, Licor Biosciences) and goat anti-mouse (Dilution – 1:  
20,000, Cat. No. 926-32210, Licor Biosciences) secondary antibodies for 1 h at room 
temperature. After washing the membranes with 1X PBS-T, the protein bands were 
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visualized on an Odyssey Infrared Imager and quantified with Odyssey software (Licor 
Biosciences). 
2.3.4 Primary dissociated dopaminergic SN and VTA neuronal culture and 
treatment  
Cultures were prepared as described in Ding et al, 2004 with minor modifications. 
Postnatal day 0 rat brains were isolated under sterile condition into cold Gey’s Balanced 
Salt Solution (1.55 mM CaCl2, 5 mM KCl, 0.22 mM KH2PO4, 1.05 mM MgCl2, 137 mM 
NaCl, 2.7 mM NaHCO3, 0.84 mM NaH2PO4, and 5.5 mM glucose pH 7.25). Coronal 
sections of the SN and VTA were isolated under a dissecting microscope. The tissue was 
then incubated in a solution containing 20 units/ml of papain and dissolved in a 
disassociation media (DM) containing 90 mM Na2SO4, 30 mM K2SO4, 5.8 mM MgCl2, 
0.25 mM CaCl2, 10 mM 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES), 
20 mM glucose, 0.5% phenol red, 1 mM kynurenic acid and 10 mM MgCl2 for 1 h in a 
roller drum incubator (Schuett-biotec Gmbh, Göttingen, Germany) at 35 C. After 
incubation in the papain, the tissue was washed several times in DM, followed by washes 
in trituration media (TM; 1 mg/ml Bovine Serum Albumin (BSA), 10 mM Hepes, 
1mg/ml trypsin inhibitor, 1 mM kynurenic acid, 10 mM MgCl2, 5% fetal bovine serum), 
then finally two washes with feeding media (FM; 2% rat serum, 2% fetal bovine serum, 
B27 Supplement Supplement (Life Technologies, Grand Island, NY), 0.225% glucose, 1 
mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 mM Hepes, and 
0.9 mM sodium pyruvate in BME). After washing, the tissue was mechanically 
dissociated with a fire-polished pipet in TM. The slurry of cells was put through a 
concentration gradient 10mg/ml BSA, 10mg/ml trypsin inhibitor, 1 mM kynurenic acid, 
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10 mM MgCl2, 5% fetal bovine serum in BME to concentrate neurons and remove debris. 
The pellet was resuspended in FM. Cells were plated on 16 well Nunc chambered slides 
(Thermofischer Scientific, Pittsburgh, PA), coated with 200 µg/ml poly-d-lysine and 5 
µg/ml laminin (Life Technologies) at a concentration of 30,000 live cells/well determined 
by trypan blue cell exclusion with a hemocytometer. Cultures were maintained at 37 C 
in 5% CO2. As soon as the cultured primary cells were attached to the plate (at least one 
hour following plating), the treatments with DMSO and MEK inhibitors, BIX02189 
(Selleck Chemicals, Houston, TX) or U0126 (Sigma-Aldrich) (all 10 µM), were 
performed for different time points (0, 1, 6, 12, and 24 h). 
2.3.5 Immunocytochemical staining 
 
At 2, 4, 6, and 8 days in vitro (DIV) slides were fixed in 4% paraformaldehyde 
and 4% sucrose in PBS for 30 min. The slides were washed 3 times in wash buffer (0.1% 
Tween 20, sodium azide in PBS). Following washes, the slides were incubated in 
blocking solution of 5% BSA (Sigma-Aldrich), 0.1% glycine, 5% goat serum (Jackson 
Immuno, West Grove, PA), and 0.3% Triton X-100 (Bio-Rad) in PBS with sodium azide 
for 1 h. After blocking, cultures were incubated in rabbit anti-TH antibody (PelFreez, 
Rogers, AR) overnight at a concentration of 1:5000 in blocking buffer. Following three 
washes, the cultures were incubated with Alexa Fluoro 546 goat anti-mouse (1:1000, 
Molecular Probes, Life Technologies) in blocking buffer 2 h and Hoechst 33342 (10 
μg/ml) for 15 min. The slides were washed and cover slipped with Fluoromount 
(Southern Biotech Birmingham, AL). 
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2.3.6 Data Collection and Image Analysis for TH+ and Hoechst counting 
 
Images were captured with MetaMorph Imaging Software (7.1, Universal 
Imaging, Downingtown, PA) using a Retiga 1300R digital CCD camera (QImaging, 
Burnaby, British Columbia, Canada). TH
+
 cells and total cell number were obtained 
using the cell count macro within the MetaMorph software after verifying the accuracy 
with manual counting of the cells. 
2.3.7 SH-SY5Y cells culture and treatment 
 
Human dopaminergic neuroblastoma SH-SY5Y cells were cultured in DMEM 
(Cat. No. 11965-084, Life Technologies) supplemented with 10% (v/v) fetal bovine 
serum (Cat. No. S11550, Atlanta Biologicals, Atlanta, GA), 0.05 units/ml penicillin and 
0.05 mg/ml streptomycin (Cat. No. P0781, Sigma-Aldrich) and maintained at 37 ºC in a 
humidified 5% CO2 atmosphere. For treatment with inhibitors, SH-SY5Y cells were 
seeded in 96-well plates (Cat. No. 3603, Black plate with clear bottom, Corning 
Incorporated, Corning, NY) at a density of 15,000 cells/well. Cell viability was assessed 
after 24 and 48 h of U0126 (10 µM) or BIX 02189 (10 µM) exposure. 
2.3.8  CellTiter-Glo® Luminescent Cell Viability Assay 
Cell viability was detected in 96-well (Cat. No. 3603, Black plate with clear 
bottom, Corning Incorporated) format using CellTiter-Glo
®
 Luminescent Cell Viability 
Assay (Cat. No. G7570, Promega Inc., Madison, WI). This assay is based on a 
luciferase/luciferin reaction. In presence of Mg
2+
 and ATP, luciferase/luciferin produces 
oxyluciferin and releases energy in form of luminescence. As this reaction requires ATP, 
the luminescence produced is proportional to the amount of ATP present.  The amount of 
ATP is directly proportional to the number of metabolically active viable cells. 
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Briefly, to determine SH-SY5Y viability, the 96-well plate was taken from the 
incubator and brought to room temperature, and 25 µl of Cell Titer-Glo mixture were 
added to each well containing 50 µl media. The cells were then lysed by shaking the plate 
at high speed for 10 min on shaker. After 10 min, Luminescence was measured on a 
microplate reader (Victor3 1420 multilabel counter, PerkinElmer, MA). 
2.3.9  Statistical Analysis  
 
 GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis. 
Data are expressed as mean ± SEM. For the aging study, statistical comparison was 
performed using a one-way analysis of variance (ANOVA) followed by the appropriate 
post hoc test as noted for each analysis. A two-tailed Student's t-test for unpaired data 
was also used for statistical comparisons. For viability studies, statistical significance was 
determined by two-way ANOVA followed by the Bonferroni post hoc test. Statistical 
significance was defined at p < 0.05.  
2.4 Results 
2.4.1 Age-related changes in ERK1, ERK2, and ERK5.  
 
 No age-related changes were observed in total ERK5 expression in the SN, STR, 
or VTA (Figs. 9-11), but found a decrease in p-ERK5 in old and middle-aged animals as 
compared to young animals in the SN and STR (Figs. 9 and 10, respectively). The decline 
in p-ERK5 with aging was observed when the ratio of p-ERK5 was taken with either α-
tubulin or total ERK5. No p-ERK5 expression was detected in the VTA (Fig. 11), which 
could be due to either low ERK5 expression or low phosphorylation in this region. 
In contrast to ERK5, age-related increases in total ERK1 expression were 
observed in the SN, STR, and VTA (Figs. 9-11). In the SN and VTA, no significant 
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changes were observed in ERK2 expression but in the VTA a trend increase in ERK2 
expression was observed starting at middle age (Figs. 9-11). This trend is significant 
when the young and middle age groups were compared using student’s t-test (p = 0.023, 
Fig. 11). We did not observe any significant changes in p-ERK1 and p-ERK2 with age in 
SN (Fig. 9) or VTA (Fig. 11). However, an increase in p-ERK2 was observed in the STR 
starting at middle age (Fig. 10) when the ratio of p-ERK2 was taken with either α-tubulin 
or total ERK2. In the VTA, trending decreases in the amount of p-ERK1 and p-ERK2 
were observed with age when the ratio of p-ERK1 and p-ERK2 were taken with total 
ERK1 and total ERK2, respectively (Fig. 11). However, this trend was not significant. 
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Figure 9: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the 
substantia nigra (SN) from young, middle-aged, and old male F344xBN F1 hybrid 
rats 
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 expression 
in the SN. 
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to α-
Tubulin and basal total protein. n=10 for each age. Data are expressed as mean ± SEM. * 
p < 0.05 indicates a difference compared to the young age group. # p < 0.05 indicates a 
difference compared to the middle age group. p values were determined by analysis of 
variance followed by post hoc Student-Newman-Keuls. 
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Figure 10: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the 
striatum (STR) from young, middle-aged, and old male F344xBN F1 hybrid rats 
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5  
expression in the STR. 
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to α-
Tubulin and basal total protein. n=10 for each age. Data are expressed as mean ± SEM. 
** p < 0.01 and * p < 0.05 compared to the young age group by analysis of variance 
followed by post hoc Student-Newman-Keuls.  
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Figure 11: Total and phosphorylated ERK1, ERK2, and ERK5 expression in the 
ventral tegmental area (VTA) from young, middle-aged, and old male F344xBN F1 
hybrid rats 
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 expression 
in the VTA.  
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to α-
Tubulin and basal total protein. n=5 for each age. Data are expressed as mean ± SEM. * p 
< 0.05 indicates a difference compared to the young age group by analysis of variance 
followed by post hoc Student-Newman-Keuls. 
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2.4.2  U0126 and BIX02189 inhibit ERK1/2 or ERK5 activation, respectively.  
 
 In order to determine the distinct roles of the ERK isoforms in the basal survival 
of DA neurons, the impact of MEK inhibitors that specifically block either ERK1 and 
ERK2 or ERK5 phosphorylation was examined by western analysis in primary cultures 
from the SN and VTA. It has been reported that the MEK1/2 inhibitor, U0126, also 
blocks MEK5 phosphorylation, thereby inhibiting ERK1/2, and 5 activation (Kamakura 
et al., 1999; Cavanaugh et al., 2006). However, others have reported that U0126 does not 
inhibit ERK5 signaling (Mody et al., 2001). This suggests that the specificity of U0126 
may depend on the type of cells, stimulation, and concentration used. Hence, it is 
important to test whether or not U0126 blocks ERK1, ERK2, and/or ERK5 
phosphorylation in our system. Results indicate that U0126 significantly blocked ERK1 
and ERK2, but not ERK5, phosphorylation in primary SN and VTA cultures at any time 
point or dose tested in this study (Figs. 12A and 12B).  
 Recently, BIX02189 was developed as a selective pharmacological inhibitor of 
the MEK5/ERK5 pathway (Tatake et al., 2008; Obara et al., 2011). Results confirm that 
BIX02189 (10 µM) blocked ERK5, but not ERK1 or ERK2,  phosphorylation at 12 and 
24 h in primary SN and VTA cultures (Figs. 12C and 12D). 
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Figure 12: Inhibition of ERK1/2 and ERK5 phosphorylation by U0126 and 
BIX02189, respectively 
Immunoblot analysis indicating selective inhibition by U0126 (10 µM) of ERK1/2 
phosphorylation in the primary dissociated neuronal culture prepared from (A) substantia 
nigra and (B) ventral tegmental area. Immunoblot analysis indicating selective inhibition 
by BIX02189 (10 µM) of ERK5 phosphorylation in the primary dissociated neuronal 
culture prepared from (C) substantia nigra and (D) ventral tegmental area. Data are 
expressed as mean ± SEM. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicates indicate a 
difference compared to the no treatment by analysis of variance followed by post hoc 
Student-Newman-Keuls. 
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2.4.3  ERK5 is necessary for the basal survival of primary SN and VTA cultures.  
 
 To examine the role of the ERK pathways in the basal survival of DA neurons, 
the SN and VTA cultures were treated with U0126 (10 µM) or BIX02189 (10 µM) on 
DIV 0 until DIV 2, 4, 6, and 8. The DA neuronal and total cell viability was then 
determined at DIV 2-8 by counting TH
+
 neurons and Hoechst-stained nuclei. As is usual 
with these primary DA cultures, a decline in the number of TH
+
 neurons and an increase 
in the number of Hoechst-stained nuclei in both the SN and VTA were observed with 
increasing DIV in the vehicle group. The TH
+
 neurons are only 5-10% of the total cells in 
culture. Therefore even as the number of DA neurons decreases, the percent of total cells 
may not decrease. In addition, the glia in the culture continues to divide with time. By 
DIV 2, treatment of SN and VTA primary cultures with BIX02189 decreased the number 
of total cells (which includes DA neurons, GABA neurons, and glia) in both the SN 
(45%; Fig. 13F) and VTA cultures (47%; Fig. 14F). This effect was even more 
pronounced when DA neurons were counted separately: DA neurons were reduced by 
67% in SN and 69% in VTA cultures (Figs. 13E and 14E, respectively). Similarly, at 
DIV 4, 6, and 8, significant losses of DA neurons and total cells were observed in the SN 
and VTA cultures treated with BIX02189 as compared to the vehicle treated cells. In 
contrast, U0126 treatment did not cause a significant decrease in DA neurons or total 
cells in cultures of the SN (Figs. 13E and 13F) or VTA (Figs. 14E and 14F) by DIV 2. A 
significant loss of DA neurons was observed at DIV 4, 6, and 8 with U0126 in the VTA 
(Fig. 14E), but not SN (Fig. 13E). Similarly, a significant loss of total cells was observed 
at DIV 4, 6, and 8 with U0126 in the VTA (Fig. 14F). In contrast, a significant decrease 
in the total number of cells was only observed at DIV 8 in the SN following U0126 
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treatment (Fig. 13F). At every time point examined the percentage loss of both DA 
neurons and total cells in the SN and VTA cultures was greater following BIX02189 
treatment as compared to U0126 treatment. When the ratio of the number of DA neurons 
to that of total cells was determined for SN and VTA cultures, there was a significant loss 
of DA neurons following BIX02189, but not U0126, treatment as compared to the 
vehicle controls for all the DIV (Figs.15A and 15B). 
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Figure 13: Effect of pharmacological inhibition of ERK1/2 and ERK5 phosphorylation on the basal survival of DA neurons in 
primary dissociated substantia nigra cultures 
 
At DIV 0  cultures were treated with U0126 (10 µM) and BIX02189 (10 µM) and cultures were fixed and immunostained for TH (red 
fluorescence) to label DA neurons and bisbenzimide H33258 (Hoechst – blue fluorescence) to label all cell nuclei on A) DIV 2, B) 
DIV 4, C) DIV 6 and D) DIV 8. Data were quantified for E) number of TH
+
 cells and F) number of total cells (Hoechst). Data are 
expressed as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference as compared to respective vehicle 
treatment by two-way ANOVA followed by the Bonferroni post hoc test. 
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Figure 14: Effect of pharmacological inhibition of ERK1/2 and ERK5 phosphorylation on the basal survival of DA neurons in 
primary dissociated ventral tegmental area cultures 
At DIV 0 cultures were treated with U0126 (10 µM) and BIX02189 (10 µM) and cultures were fixed and immunostained for TH (red 
fluorescence) to label DA neurons and bisbenzimide H33258 (Hoechst – blue fluorescence) to label all cell nuclei on A) DIV 2, B) 
DIV 4, C) DIV 6 and D) DIV 8. Data were quantified for E) number of TH
+
 cells and F) number of total cells (Hoechst). Data are 
expressed as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 indicates a difference as compared to 
respective vehicle treatment by two-way ANOVA followed by the Bonferroni post hoc test. 
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Figure 15: Ratio of TH+ cells to total cell counts 
Loss of TH
+
 cells with respect to total cell loss in primary dissociated neuronal cultures prepared from A) substantia nigra and B) 
ventral tegmental area for all the DIV. Data are expressed as mean ± SEM. Data are expressed as mean ± SEM. * p < 0.05 indicate a 
difference as compared to respective vehicle treatment by two-way ANOVA followed by the Bonferroni post hoc test. 
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2.4.4 ERK5 is necessary for basal survival of SH-SY5Y cells.  
 
 Primary dissociated SN and VTA cultures contain other neuronal cell types 
(e.g., GABA neurons) and glia that have been shown to protect DA neurons against 
oxidative stress (Hou et al., 1997). Thus, it is possible that the MEK inhibitors were 
influencing DA neurons indirectly via the inhibition of ERK signaling in other cells. In 
an attempt to examine this possibility, the effect of MEK inhibitors was tested on the 
human neuroblastoma SH-SY5Y cell line which has been shown to possess many 
characteristics of dopaminergic neurons, including the presence of TH and dopamine β-
hydroxylase and the capacity to synthesize DA (Biedler et al., 1973; Oyarce and Fleming, 
1991; Cheung et al., 2009; Xie et al., 2010). SH-SY5Y cells were treated with U0126 (10 
µM) or BIX02189 (10 µM) for 24 and 48 h. Our results show a loss of SH-SY5Y cell 
viability with BIX02189, but not U0126, treatment at 24 and 48 h (Fig. 16).   
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Figure 16: Effect of pharmacological inhibition of ERK1/2 and ERK5 
phosphorylation on the basal survival of human dopaminergic neuroblastoma SH-
SY5Y cells 
SH-SY5Y cells were treated with U0126 (10 µM) and BIX02189 (10 µM) for 24 and 48 
h. After 24 and 48 h, cell viability was determined by measurement of ATP levels using a 
Cell Titer-Glo Luminescent Cell Viability Assay. Data are expressed as mean ± SEM. ** 
p < 0.01 and *** p < 0.001 indicates a difference as compared to respective vehicle 
treatment by two-way ANOVA followed by the Bonferroni post hoc test. 
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2.5 Discussion 
 
This study examined the levels of total and phosphorylated ERK 1, ERK2, and 
ERK5 in several dopaminergic brain regions as a function of age. Furthermore, this study 
sought to determine the importance of ERK phosphorylation in the survival of DA 
neurons emanating from the SN and VTA. In contrast to previous studies in which no 
ERK5 mRNA or protein expression was detected in the SN, STR, and VTA of the adult 
mouse brain (Di Benedetto et al., 2007; Pan et al., 2012), detection of both total and 
phosphorylated ERK5 protein in each adult brain region examined with the exception of 
p-ERK5 in the VTA was observed in this study. Unpublished data from our laboratory 
indicated detection of ERK5 expression using immunohistochemistry and western blot in 
the same strain of mice (C57BL/6) used above mentioned strain (Di Benedetto et al., 
2007; Pan et al., 2012). Therefore, this difference could be associated with the primary 
ERK5 antibody and/or the technique used for detection. For example, Pan and colleagues 
used an ERK5 antibody generated in their laboratory. Moreover, Pan and colleagues 
(2012) used immunohistochemistry to detect ERK5 protein and Di Benedetto and 
colleagues (2007) used in situ hybridization to detect mRNA. Neither group performed 
western blot analysis to confirm the presence of ERK5 protein in adult brain. Using 
western blot analysis, several studies have reported the presence of ERK5 in several adult 
brain regions such as the hippocampus and cortex/prefrontal/frontal cortex in humans and 
rodents (Yoon et al., 2005, Liu et al., 2006, Dwivedi et al., 2007). Our findings suggest 
that while total ERK 1, 2, and 5 and phosphorylated ERK 1 and 2 either remain 
unchanged or increase with age in the SN, STR, and VTA, ERK5 phosphorylation 
decreases with age in the SN and STR. Moreover, inhibition of ERK5 phosphorylation by 
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BIX02189 reduced the survival of cultured DA neurons with little effect of inhibition of 
ERK 1 and 2. The function and viability of dopaminergic neurons depend on the 
availability of neurotrophic factors and subsequent activation of survival signaling 
(Lindgren et al., 2008; Pascual et al, 2008; Kim et al., 2011; Hidalgo-Figueroa et al., 
2012). This study highlights the importance of ERK5 signaling in supporting the viability 
of dopamine neurons that may play a crucial role in maintaining mature dopaminergic 
neurons during adulthood.  
ERK 1, 2, and 5 as a function of age: In the present study, with age a decrease in 
ERK5 phosphorylation in the SN and STR by old and middle-age, respectively (Figs. 9-
10) was observed. The differences in the decline of p-ERK5 in the SN and STR at 
different ages could be regional/localization specific.  In the STR, the increased levels of 
p-ERK5 at the old age after a significant decline at the middle-age could be associated 
with decreased phosphatase activities by the old age. In addition, an increase in ERK2 
phosphorylation was observed in the STR with age (Fig. 9). These data suggest the 
possibility that cross-talk between these signaling pathways might occurs in the STR such 
that an increase p-ERK2 expression occurs to compensate for the decrease in p-ERK5. 
Evidence for cross-talk between the ERK1, 2, and 5 pathways has been previously 
suggested (Mody et al., 2001; Barros and Marshall, 2005). For example, pharmacological 
inhibition of ERK1 and 2 phosphorylation leads to a sustained activation of MEK5 and 
ERK5 following growth factor stimulation in HeLa cells (Mody et al., 2001).  
Role of ERK5 in the survival of DA neurons: Previously, we have reported that 
ERK1, 2, and 5 are important for the basal survival of MN9D cells (Cavanaugh et al., 
2006). However, this phenomenon had not been tested previously in primary DA 
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neuronal cultures due to the lack of specific pharmacological inhibitors of the 
MEK5/ERK5 pathway. The development of these specific inhibitors, such as BIX02189, 
has allowed comparison of the roles of ERK1/2 and ERK5 isoforms in the basal survival 
of primary dissociated SN and VTA cultures. Using BIX02189 as a specific inhibitor of 
the upstream ERK5 kinase, MEK5, we observed a significant loss of DA neurons, total 
cells, and the number of DA neurons as a percentage of the total cells starting at DIV 2 in 
the SN and VTA cultures (Figs. 13-15). In contrast, U0126, an inhibitor of ERK1/2 
phosphorylation had no such effect at DIV 2 in the SN and VTA cultures (Figs. 13-15). 
Similarly, in SH-SY5Y cells, cell viability significantly decreased following treatment 
with BIX02189, but not U0126 (Fig. 16). However, following U0126 treatment there is a 
significant decline in the DA neurons and total cells at later time points (DIV 4, 6, and 8) 
in the VTA culture (Fig. 14). Although not significant, the percentage loss of DA neurons 
and total cells in the SN culture were similar to the VTA culture following U0126 
treatment at DIV 4, 6 and 8. These data suggest that a loss of ERK1/2 signaling during 
early DIV results in an increased vulnerability of SN and VTA DA neurons and other 
cells at later time points. However, the number of DA neurons as a ratio of total cells is 
not decreased in these same cultures at any time point following U0126 treatment (Fig. 
15). The VTA DA neurons have shown to be more resistant to cell death in vivo and in 
vitro experiment models (Okamura et al., 1995; Ding et al., 2004) and PD (Uhl et al., 
1985; German et al., 1989) as compared to the SN DA neurons. However, blocking the 
ERK5 signaling resulted in approximately equal percentages of DA neuronal-death; 
indicating that ERK5 is necessary for the basal survival of DA neurons, in both, the SN 
and VTA. These results are in accordance with a previous study in which targeted 
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deletion of ERK5 in the developing nervous system reduced the density of dopaminergic 
neurons in the olfactory bulb (Zou et al., 2012).  
Possible relation to neurotrophic factors: Loss of motor functions and PD are 
associated with an age-related loss of nigral DA neurons (Eriksen et al., 2009; Fearnley 
and Lees, 1991; Fox et al., 2001; Morgan et al., 1987) and/or dysfunction in the 
nigrostriatal dopaminergic pathways (Carlsson and Winblad 1976; McGeer et al., 1977; 
Irwin et al. 1994; Gerhardt et al., 1995; Yurek et al., 1998; Yue et al., 2012). These DA 
neuronal impairments may be associated with the age-related decline in ERK5 activation 
in the SN (DA neuronal cell-body containing region) as observed in the present study. 
Neurotrophic factors (NTFs) essential for DA neuron survival, including glial cell line-
derived neurotrophic factor (GDNF), brain derived neurotrophic factor (BDNF), nerve 
growth factor (NGF) and neuregulin (NRG), have been shown to activate the ERK5 
pathway (Carlsson et al., 2011; Cavanaugh et al., 2001; Dickerson, 2010; Esparis-Ogando 
et al., 2002; Fox et al., 2001; Hayashi et al., 2001; Obara et al., 2009). Moreover, a 
critical role for ERK5 in NTF-induced survival of immature cortical, cerebellar, dorsal 
root ganglia, and superior cervical ganglion neurons has been reported (Watson et al., 
2001; Liu et al., 2003; Shalizi et al., 2003; Finegan et al., 2009). Age-related declines in 
GDNF protein and GDNF and NRG receptors (GFR α-1 and ErbB4, respectively) have 
been noted in dopaminergic brain regions (Yurek and Fletcher-Turner, 2001; Dickerson 
et al., 2009; Pruett and Salvatore, 2010) and several NTFs are particularly low in the SN 
of patients with Parkinson’s disease (Jenner and Olanow, 1998; Mogi et al., 1999; Siegel 
and Chauhan, 2000).     
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  These observations, along with our current data, suggest that age-associated 
declines in nigral DA neurons (Morgan et al., 1987; Fearnley and Lees, 1991; Fox et al., 
2001; Eriksen et al., 2009) and motor functions (Irwin et al., 1994; Bennett et al., 1996; 
Boger et al., 2006; Allen et al., 2011; Yue et al., 2012) could be a consequence of 
decreased ERK5 activation resulting from reduced NTF signaling. Moreover, inhibition 
of the ERK5 pathway has been shown to reduce GDNF mRNA and protein levels in 
some cells (Obara et al., 2011), suggesting a feedback loop in which MEK5-ERK5 
signaling is further decreased. 
In conclusion, we present evidence for age-related changes in total and 
phosphorylated ERK1, 2, and 5 in DA-rich brain regions during normal aging. The 
expression and activation changes in ERK1, 2, and 5 with aging appears to be different in 
different dopaminergic brain regions, possibly, indicating their specific role, which need 
to be elucidated. Further, we have elucidated distinct roles of ERK1, 2, and 5 in the basal 
survival of DA neurons and total cells in SN and VTA primary cultures. As our data 
suggest that ERK5 activation is essential for the survival of dopaminergic neurons, the 
use of NTFs that activate ERK5 could be a viable therapeutic option to decrease DA 
neuronal vulnerability and, thereby, reduce age-related motor deficits and the risk of PD. 
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Chapter 3: Postnatal developmental changes in ERK’s protein expression and 
activation. 
3.1 Rationale:  
 
Early development of dopaminergic midbrain areas, such as SN and VTA and 
their dopaminergic inputs into STR are precisely controlled by numerous factors, 
including cellular signaling pathways and transcription factors (Ries et al., 2009). Toxic 
or harmful exposure to these brain regions during prenatal or postnatal development 
could alter cellular signaling pathways and lead to deformation of the dopaminergic 
circuit, resulting in neurodegenerative and neuropsychiatric disorders early or later in life. 
Hence, elucidating changes in cellular signaling pathways that might be occurring during 
postnatal development of dopaminergic brain regions such as SN, VTA, and STR, will 
facilitate the understanding of dopamine neuronal dysfunction during disabling 
neurologic and psychiatric diseases. Recently, we have shown that blocking the ERK 
signaling pathways in primary dopaminergic neurons using specific inhibitors as early as 
day in vitro (DIV) 0 resulted into significant loss of viability at DIV 2, 4, 6, and 8 
(Chapter 2). Moreover, previous studies have shown that ERK5 levels are highest during 
early prenatal development (Liu et al., 2003, 2006). In contrast to ERK5, low expression 
of ERK1 and ERK2 has been observed during early development of the nervous system 
(brain and spinal cord; Boulton et al., 1991; Liu et al., 2003) and the expression of ERK1 
and 2 increases during postnatal development (Boulton et al., 1991). Together these data 
suggest that ERK pathways are necessary for basal survival of dopaminergic neurons 
during early time points and may play crucial role in the development of dopaminergic 
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brain regions. However, no research has studied postnatal developmental changes in 
these ERK kinases in dopaminergic brain regions, such as SN, VTA, and STR.  
3.2 Hypothesis: 
 
ERK5 activation decreases and ERK1/2 activation increases with postnatal development 
in dopaminergic brain regions. 
3.3  Materials and Methods 
3.3.1  Animals 
 
Time pregnant and adult Sprague-Dawley rats (Charles River) were adapted to a 
12:12 h light:dark cycle and provided with water and Purina Rat Chow ad libitum. All 
procedures were conducted in accordance with the guidelines for the NIH Care and Use 
of Laboratory Animals and approved by the University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC).  Rats from different post developmental stages 
(postnatal days 0, 7, 10, 14 and adult, n = 3) were used.  
3.3.2  Materials and tissue preparation 
  The SN, STR, and VTA tissues were isolated from pups brain at day 0, 7, 10 and 
14 and adult brain at 0 °C on ice, and frozen using dry ice. Later tissues were stored at - 
80 °C until analysis. Tissues were homogenized as shown in lysis buffer as described in  
Chapter 2 (2.3.2 section).  
3.3.3 Western blot analysis 
 
Western blot analysis was performed as described in Chapter 2. Antibodies included 
rabbit anti-phospho-ERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling,), mouse 
anti-total ERK1/2 (Dilution – 1:2000, Cat. No. 9107, Cell Signaling) and rabbit anti-total 
ERK5 (Dilution – 1:1,000, Cat. No. 3372, Cell Signaling). Mouse anti-α-Tubulin 
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(Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a loading control. The 
secondary antibodies used were goat anti-rabbit (Dilution – 1:  20,000, Cat. No. 926-
68021, Licor Biosciences) and goat anti-mouse (Dilution – 1:  20,000, Cat. No. 926-
32210, Licor Biosciences). 
3.3.4 Statistical Analysis 
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis. 
Data are expressed as mean ± SEM. Statistical comparison was performed using a one-
way analysis of variance (ANOVA) followed by post hoc Dunnet's test. Statistical 
significance was defined at p < 0.05.  
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3.4  Results: 
3.4.1 ERK5 and ERK1/2 are differentially regulated in the SN during postnatal 
brain development. 
 ERK5 and p-ERK5 expression levels decreased during postnatal development in 
the SN with significant decline of ERK5 at PND10 and  decline in p-ERK5 starting at 
PND10 as compared to PND0 (Fig. 17). The amount of ERK5 activation (i.e. p-
ERK5/ERK5) decreased significantly starting at PND14 as compared to PND0 (Fig. 17). 
A peak and significant increase in p-ERK1 and p-ERK2 expression levels was observed 
at PND7, followed by decline at PND10 and PND14 to the level of adult age (Fig. 17). 
Similar to p-ERK1 and p-ERK2 levels, the amount of ERK1 and ERK2 activation (i.e.  p-
ERK1/ERK1 and p-ERK2/ERK2) increased significantly at PND7, followed by decline 
at PND10 and PND14 to the degree of adult age (Fig. 17). Interestingly, as ERK5 
expression declines with postnatal development, a trend increase in ERK1 and a 
significant increase in ERK2 are observed with the highest expression levels observed at 
adult age (Fig. 17).  
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Figure 17: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the 
substantia nigra (SN) during postnatal brain development 
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in SN were examined by 
immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at 
various ages postnatal (PND0 - PND14) and from adult rat brain. Phosphorylation of 
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band.  
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to the 
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ± 
SEM.* p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the 
PND0. 
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3.4.2 ERK5, ERK1 and ERK2 are differentially regulated in the VTA during 
postnatal brain development. 
 ERK5 and p-ERK5 expression levels decreased with postnatal development in the 
VTA with a significant decrease in ERK5 expression by adult age and p-ERK5 starting at 
PND14 as compared to PND0 (Fig. 18). The amount of ERK5 activation (i.e.  p-
ERK5/ERK5) decreased significantly starting at PND14 as compared to PND0 (Fig. 18), 
similar to p-ERK5 levels.  A biphasic alteration in p-ERK1 and p-ERK2 expression 
levels was observed during postnatal development in the VTA such that increases in p-
ERK1 and p-ERK2 levels are observed at PND7 and PND14 as compared to PND0 (Fig. 
18). The amount of ERK1 activation (i.e.  p-ERK1/ERK1) was significantly increased at 
PND7 and PND14, while the amount of ERK2 activation (i.e. p-ERK2/ERK2) was 
significantly high at PND7 only as compared to PND0 (Fig. 18). Interestingly, while 
ERK5 expression decreases with postnatal development, a trend increase in ERK1 and in 
ERK2 is observed with the highest expression levels observed at adult age (Fig. 18). 
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Figure 18: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the 
ventral tegmental area (VTA) during postnatal brain development 
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in VTA were examined 
by immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at 
various ages postnatal (PND0-PND14) and from adult rat brain. Phosphorylation of 
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band.  
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to the 
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ± 
SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the 
PND0.  
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3.4.3 ERK5, ERK1 and ERK2 are differentially regulated in the STR during 
postnatal brain development. 
 ERK5 and p-ERK5 expression levels significantly decreased with postnatal 
development in the STR starting at PND7 and continuing to adult age as compared to 
PND0 (Fig. 19). Similar to ERK5 and p-ERK5 expression levels, a significant decrease in 
p-ERK1 and p-ERK2 expression levels was observed with postnatal development at 
PND7 through adult age as compared to PND0 (Fig. 19). The amount of ERK1 and 
ERK2 activation (i.e.  p-ERK1/ERK1 and p-ERK2/ERK2) is also significantly decreased 
as compared to PND0 (Fig. 19), similar to p-ERK1 and p-ERK2 expression levels. 
Although declines in phosphorylated ERK1, ERK2, and ERK5 and total ERK5 
expressions were noted with postnatal development, a trend increase in ERK1 and a 
significant increase in ERK2 were observed with the highest expression observed at adult 
age (Fig. 19). 
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Figure 19: Expression of total and phosphorylated ERK1, ERK2, and ERK5 in the 
striatum (STR) during postnatal brain development 
A) Levels of total and phosphorylated ERK1, ERK2, and ERK5 in STR were examined 
by immunoblotting using equal amount of protein (60 µg/lane) isolated from rat brain at 
various ages postnatal (PND0-PND14) and from adult rat brain. Phosphorylation of 
ERK5 is indicated by an electrophoretic mobility shift of the ERK5 band. 
B) Quantification of the immunoblots using Licor Odyssey software. The values are 
calculated using the integrated intensity. Protein expression was standardized to the 
intensity of α-Tubulin and total protein. n = 3 for each age. Data are expressed as mean ± 
SEM. * p < 0.05, ** p < 0.01 and *** p < 0.001 indicates a difference compared to the 
PND0.  
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3.5 Discussion 
 
To examine the MAPKs signaling alterations in the postnatal development of the 
SN, VTA, and STR, the protein levels of total (non-phosphorylated) and 
phosphorylated/activated ERK1, ERK2, and ERK5 were measured at different postnatal 
ages. In contrast to previous studies in which no ERK5 mRNA or protein was detected in 
the dopaminergic brain regions of the adult mouse or the brain as a whole (Di Benedetto 
et al., 2007; Pan et al., 2012), both total and phosphorylated ERK5 protein were detected 
in each of the aforementioned brain regions in the postnatal and adult brain (Figs. 17-19). 
The expression levels of activated ERK1 (i.e. p-ERK1) and ERK2 (i.e. p-ERK2)  
in the dopaminergic brain regions, SN and VTA, changed considerably during postnatal 
development, with a peak at PND7 in SN and biphasic peaks at PND7 and PND14  in 
VTA (Figs. 17-18). In contrast, in the STR, the expression of p-ERK1 and p-ERK2 was 
significantly lower beginning at PND7 until adult age relative to PND0 (Fig. 19). 
However, with postnatal development an increase in total ERK1 and/or ERK2 expression 
are observed in all dopaminergic brain regions. This is in accordance with an observance 
made by Boulton and colleagues (1991), indicating lower expression of ERK1 and ERK2 
in the nervous system (brain and spinal cord) during embryonic development and 
increase in their expression with postnatal development.  ERK5 and p-ERK5 expression 
were highest at early postnatal development days and gradually subsided as the brain 
matured. This is in accordance with data reported by Liu and colleagues (2003, 2006) that 
showed highest expression of ERK5 and/or p-ERK5 in cortex and whole brain during 
early embryonic development but declined as the brain matures with postnatal 
development. Overall, with a decline in total and phosphorylated ERK5 a concurrent 
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increase in total ERK1 and/or ERK2 is observed in the SN, STR and VTA regions with 
postnatal development (Figs. 17-19). This pattern of expression suggests that ERK5 may 
be necessary for early development, and ERK1 and/or ERK2 for later postnatal 
development of nigrostriatal and mesolimbic system. As shown in Chapter 2 (Figs. 13-
15) inhibition of ERK5 activation in PND0 primary dopamine neuronal in vitro cultures 
from SN and VTA resulted in significant losses of TH
+
 dopamine neurons at early days 
in vitro (Chapter 1); while inhibition of ERK1/2 activation did not lead to a significant 
loss of TH
+
 dopamine neurons until later time points. Together these data indicate that 
ERK5 may be necessary for dopaminergic neurons survival during early pre- and 
postnatal SN and VTA development, while ERK1/2 is necessary for postnatal survival 
later in development and aging.  
In SN, VTA, and STR tissues, the alterations in ERK kinases (Figs. 17-19) during 
postnatal development could be contributing to several processes that occur during the 
development of rat nigrostriatal and mesolimbic systems, such as maintenance of 
neuronal viability, integrity of already differentiated neurons, DA neuronal natural cell 
death event in the SNc, differentiation of DA terminals in the STR, increases in TH 
activity, and increases in synapse density in STR and SNc (Burke, 2003). Changes in the 
levels of neurotrophic factors, such as GDNF, with postnatal development have been 
noted in STR and SN (Cho et al., 2003). For instance, after birth or during early postnatal 
development, GDNF mRNA and protein levels are high in the STR and SN and decrease 
with age (Blum et al., 1995; Lopez-Martin et al., 1999; Cho et al., 2003). These 
alterations in ERK signaling could be the result of changes in physiological levels of 
these neurotrophic factors, which are required for survival and postnatal development to 
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of SN DA neurons (Burke, 2003; Oo et al., 2009). These neurotrophic factors been shown 
to activate these ERKs (Cavanaugh et al., 2001; Hayashi et al., 2001; Obara et al., 2011).  
The neurophysiological role of ERKs changes during first two weeks of postnatal 
development is not clear at this time.  Hence, the use of specific MEK inhibitors to block 
ERK1, ERK2, and/or ERK5 signaling during early postnatal development would allow 
determination of their specific role in development of nigrostriatal and mesolimbic 
systems.  
In conclusion, with postnatal development differences in expression pattern of 
ERK1, ERK2, and ERK5 were observed in all the three-dopaminergic brain regions. 
Similar to previously reports, higher expression of ERK5 was observed at early PND that 
declined with postnatal development, while lower expression of ERK1/2 was observed at 
early PND that increased the postnatal development. An understanding of the differences 
in expression patterns of the ERKs during postnatal development may provide significant 
insights into their role in the development of dopaminergic system. 
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Chapter 4: GDNF and DNSP-11-mediated protection against oxidative-stress 
induced toxicity. 
4.1  Rationale 
 
Glial cell line-derived neurotrophic factor (GDNF) is a potent neurotrophic factor 
that may be a promising therapeutic agent for the treatment of Parkinson’s disease (PD). 
The ability of GDNF to protect dopamine neurons against several neurotoxins, including 
MPTP and 6-hydroxydopamine (6-OHDA)(Kearns and Gash, 1995; Kearns et al., 1997; 
Hoffer et al., 1994; Hou et al., 1996) and to improve parkinsonian symptoms (Gash et al., 
1996; Grondin et al., 2002; Smith and Cass, 2007), lead GDNF into clinical trials. 
However, due to concerns related to its delivery problem, inter-trial variability among 
clinical studies, development of safety concerns due to detection of antibodies against 
GDNF in 10% of the patients undergoing the trial, and observed toxicity in the 
cerebellum of non-human primates caused the discontinuation of the trial (Gill et al., 
2003; Slevin et al., 2005, 2006; Lang et al., 2006; Salvatore et al., 2006). Despite these 
setbacks, GDNF was effective in relieving PD symptoms (Gill et al, 2003; Slevin et al., 
2005). Due to this effectiveness of GDNF, a search for a new neurotrophic factor, peptide 
or molecule that has similar beneficial neuroprotective effects is ongoing. Recently 
dopamine neuron stimulating peptide-11 (DNSP-11), a pro-peptide molecule of GDNF, 
has been made and shows promise in protecting dopaminergic neurons against neuronal 
toxicity (Bradley et al., 2010; Sonne, 2013). For example, DNSP-11 restored 
dopaminergic activity in a 6-OHDA lesion rat model (Bradley et al., 2010; Fuqua, 2010; 
Sonne, 2013). Moreover, DNSP-11 has been shown to prevent dopaminergic cell loss 
following exposure to several other neurotoxins (Bradley et al., 2010, 2013). However, 
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the molecular mechanisms of DNSP-11-medicated neuroprotection are still unclear. 
Hence, the objective of this study was to determine whether DNSP-11 protects human 
dopaminergic neuroblastoma SH-SY5Y cells against neurotoxin-induced toxicity and to 
elucidate the cellular signaling mechanisms that may be involved in DNSP-11-mediated 
protection. 
4.2  Hypothesis 
 
GDNF and DNSP-11 inhibit neurotoxin-mediated toxicity in human dopaminergic 
neuroblastoma SH-SY5Y cell line via activation of the ERK signaling pathways. 
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4.3 Materials and Methods 
4.3.1  Animals  
 
Adult (3-4 months) Fisher 344 rats (Harlan, Indianapolis, IN) were adapted to a 
12:12 h light: dark cycle and provided with water and Purina Rat Chow ad libitum. All 
procedures were conducted in accordance with the guidelines for the NIH Care and Use 
of Laboratory Animals and approved by the Duquesne University Institutional Animal 
Care and Use Committee (IACUC).   
4.3.2  Western blot analysis 
 
Western blot analysis was performed as described in chapter 2. Cell lysates and 
tissue lysates were centrifuged at 11,000 rpm for 30 min at 4 ºC and the supernatant was 
collected and stored at -80 ºC.  For cell lysates, 30 μg and for tissue lysates, 60 μg of 
protein was loaded on an 8% SDS-PAGE gel. Antibodies included rabbit anti-phospho-
ERK1/2 (Dilution – 1:1000, Cat. No. 9101, Cell Signaling), mouse anti-total ERK1/2 
(Dilution – 1:2000, Cat. No. 9107, Cell Signaling), anti-phospho-ERK5 (Cat. No. 3371, 
Cell Signaling) and rabbit anti-total ERK5 (Dilution – 1:1,000, Cat. No. E1523, Sigma-
Aldrich). Mouse anti-α-Tubulin (Dilution – 1:10,000, Cat. No. T5168, Sigma–Aldrich) 
was used as a loading control. The secondary antibodies used were goat anti-rabbit 
(Dilution – 1:20,000, Cat. No. 926-68021, Licor Biosciences) and goat anti-mouse 
(Dilution – 1:20,000, Cat. No. 926-32210, Licor Biosciences). 
4.3.3  SH-SY5Y cells culture and treatment 
 
Cells were cultured as described in Chapter 2 (2.3.7 section). 
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4.3.4  6-Hydroxydopamine treatment 
 
For viability experiments, SH-SY5Y cells were plated at 15,000 cells per well in 
triplicate in 96-well plates (Cat. No. 3603, Black plate with clear bottom, Corning 
Incorporated), and treatments were performed 48 h after plating.  On the day of 
treatment, serum-containing media was withdrawn from the wells and replaced with 
serum-free media. The cells were serum starved for 6 h and treated with freshly prepared 
6-OHDA (6-Hydroxydopamine hydrochloride, Cat. No. H4381, Sigma-Aldrich) solution. 
The 6-OHDA solution was prepared in vehicle containing metal chelator 
diethylenetriaminepentaacetic acid (DETAPAC; 10 mM; Cat. No. D6518, Sigma-
Aldrich) and ascorbic acid (0.15%, Cat. No. A61-100, Fisher Scientific, Pittsburgh, PA) 
that is flushed with argon for 10 min while the solution was sitting on ice. Argon flush 
allowed minimization of the extracellular oxidation of 6-OHDA. First, 10 mM stock 
solution of 6-OHDA was prepared in above vehicle, followed by 1 mM solution in 
media, which was added to the wells containing media to give 100 µM of treatment. 
Unless otherwise noted, treatment with 6-OHDA was carried out for 30 min. After 30 
min, the 6-OHDA-containing media was removed to halt the 6-OHDA treatment and the 
cells were incubated in fresh standard serum-free media for 24 h (for CTG viability 
assay) and 6 h (for caspase 3/7 activity assay). The effects of 6-OHDA were always 
compared with the effects of its vehicle. 
4.3.5  GDNF and DNSP-11 treatment 
 
For viability and caspase 3/7 activity experiments, SH-SY5Y cells were plated at 
15,000 cells per well in triplicate in 96-well plates (Cat. No. 3603, Black plate with clear 
bottom), and treatments were performed 48 h after plating. On the day of treatment, 
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serum containing media was withdrawn from the wells and replaced with media without 
serum. The cells were serum starved for 6 h. After 6 h of serum starvation, cells were pre-
treated with GDNF (Cat. No. G240, Alomone Labs, Jerusalem, Israel) or DNSP-11(Cat. 
No. D8571, Sigma-Aldrich) for 1 h followed by 30 min treatment with 6-OHDA. GDNF 
or DNSP-11 was present during treatment with 6-OHDA.  After 30 min of 6-OHDA 
treatment, the GDNF or DNSP-11 and 6-OHDA-containing media is removed and the 
cells are incubated with fresh standard serum-free media containing GDNF or DNSP-11 
for 24 h (for CTG viability assay) and 6 h (for caspase 3/7 activity assay). The protective 
effects of GDNF and DNSP-11 in presence of 6-OHDA were always compared with the 
effects of 6-OHDA alone. 
4.3.6  CellTiter-Glo® Luminescent Cell Viability Assay 
  
See Chapter 2 (2.3.8). 
4.3.7  Caspase-Glo® 3/7 Activity Assay 
 
  The activity of caspase-3 and caspase-7 was detected in 96-well (Cat. No. 3603, 
Black plate with clear bottom, Corning Incorporated) format using the Caspase-Glo
®
 3/7 
Assay (Cat. No. G8091, Promega Inc., Madison, WI). This assay is a luminescent assay 
that measures caspase-3 and -7 activities in purified enzyme preparations or cultures of 
adherent or suspension cells. The assay provides a proluminescent caspase-3/7 substrate, 
which contains the tetra peptide sequence DEVD. This substrate is cleaved by caspase- 
3/7 to release aminoluciferin, a substrate of luciferase used in the production of light.  
Briefly, 100 µl of the Caspase-Glo 3/7 reagent were added to each well containing 
100 µl of media and then the contents of wells were gently mixed using a plate shaker at 
300-500 rpm for 30 seconds. The plate was then incubated at room temperature for 1 h. 
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Luminescence was measured on a microplate reader (Victor3 1420 multilabel counter, 
PerkinElmer, MA). 
 
 
 
 
Figure 20: Caspase-3/7 cleavage of the luminogenic substrate containing 
the DEVD sequence 
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4.3.8  Intrastriatal infusion of DNSP-11 
 
Animals (n = 5 /group) were anesthetized with isoflorane and placed in a Kopf 
stereotaxic apparatus (David Kopf Instruments, Tujunga, CA). DNSP-11 (Cat. No. 
D8571, Sigma-Aldrich) was infused unilaterally (30 µg) into the STR using a Hamilton 
syringe (10 µl, 701SN 30/2”/3, Cat. No. 80308, Hamilton Company, Reno, NV) in 
accordance with a stereotaxic rat brain atlas (Paxinos and Watson, 1997). DNSP-11 was 
dissolved in pH 5 Citrate Buffer (150 mM NaCl and 10 mM Sodium Citrate). The 
following stereotaxic coordinates from bregma were used to deliver the infusion 
solutions: anterior posterior (AP): + 0.3 mm, medial lateral (ML): + 2.7 mm, dorsal 
ventral (DV): - 5.6 mm. An infusion rate of 0.5 μl/minute over 12 min was controlled by 
the Stoelting Quintessential Injector (Cat. No. 53311, Stoelting Co., Wood Dale, IL) to 
deliver 6 μl of the DNSP-11 or citrate vehicle buffer treatment solution to the infusion 
site in the STR. In order to allow DNSP-11 or citrate vehicle buffer to diffusion into the 
tissue and minimize leakage while syringe withdrawal, the syringe was left in place for 5 
min after the infusion was terminated. Control animals received injections of citrate 
vehicle buffer) only. Animals were killed through decapitation and brain tissue, STR and 
SN, were isolated at different time points (2 h, 6 h, 24 h and 7 days) post DNSP-11 or 
vehicle infusion. 
4.3.9  Statistical Analysis 
 
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis. 
Data are expressed as mean ± SEM. For viability studies, statistical significance was 
determined by two-way ANOVA followed by the Bonferroni post hoc test.  For DNSP-
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11 infusion study, statistical significance was determined using a two-tailed Student's t-
test for unpaired data. Statistical significance was defined at p < 0.05. 
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4.4  Results 
4.4.1  6-OHDA treatment causes concentration-dependent toxicity in SH-SY5Y 
cells. 
Exposure to 6-OHDA for 30 min produced a concentration-dependent decrease in 
the viability of SH-SY5Y cells measured at 24 h following 6-OHDA using a CTG assay 
(Fig. 21).  The percentage loss of viability with 50, 100, and 200 µM 6-OHDA treatment 
was 13, 50, and 66%, respectively (Fig. 21). For all subsequent experiments, we used 100 
µM 6-OHDA concentrations to detect changes in cell viability. 
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Figure 21: 6-OHDA-induced toxicity in SH-SY5Y cells 
SH-SY5Y cells were treated with 6-OHDA (0, 50,100 and 200 µM) for 30 min, the 
media containing 6-OHDA was replaced with fresh media, and a CTG viability assay was 
performed 24 h post 6-OHDA treatment. Data are expressed as mean ± SEM. The data 
are averages of triplicates from 6-9 independent experiments. Statistical significance was 
determined by one-way ANOVA followed by post hoc Dunnet's test. * p < 0.05, ** p < 
0.01,  and *** p < 0.001 indicates a difference compared to the vehicle control  (6-
OHDA; 0 µM). 
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4.4.2 Pretreatment with GDNF or DNSP-11 does not protect SH-SY5Y cells 
against 6-OHDA toxicity. 
SH-SY5Y cells were treated with GDNF or DNSP-11 and 6-OHDA as described 
in the methods section. Pretreatment with GDNF (50 and 100 ng/ml) or DNSP-11 (1, 10, 
100, 500 and 1000 ng/ml) did not protect SH-SY5Y cells against 6-OHDA-induced 
toxicity (Figs. 22A and 22B). 
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Figure 22: GDNF and DNSP-11 did not protected SH-SY5Y cells against 6-OHDA-
induced toxicity 
SH-SY5Y cells were pretreated for 1 h with A) GDNF (0, 10 and 50 ng/ml) and B) 
DNSP-11 (0,1,10,100,500 and 1000 ng/ml) followed by 6-OHDA (100 µM; 30 min) 
treatment. The media containing 6-OHDA was removed, replaced with fresh media 
containing GDNF or DNSP-11, and a CTG viability assay was performed 24 h post 6-
OHDA treatment. Data are expressed as mean ± SEM. The data are averaged of 
triplicates from 3 independent experiments. Statistical significance was determined by 
two-way ANOVA followed by the Bonferroni post hoc test. **** p < 0.0001 indicates a 
difference compared to the vehicle control (6-OHDA; 0 µM). 
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4.4.3  6-OHDA treatment increases Caspase-3/7 activity in SH-SY5Y cells.  
 
Treatment with 6-OHDA was performed as described in the method section. A 
significant increase in caspase-3/7 activity was observed following 6-OHDA treatment 
for 6 h (Fig. 23). Caspase-3/7 activity declined in 6-OHDA (200 µM) treatment to the 
level of control (Fig. 23). 
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Figure 23: 6-OHDA- induced increase in caspase-3/7 activity 
SH-SY5Y cells were treated with 6-OHDA (0, 50,100 and 200 µM; 30 min) for 30 min, 
the media containing 6-OHDA was replaced with fresh media, and a caspase-3/7 assay 
was performed 6 h post 6-OHDA treatment.  Data are expressed as mean ± SEM. The 
data are averaged of triplicates from 3-6 independent experiments. Statistical significance 
was determined by one-way ANOVA followed by post hoc Dunnet's test. *** p < 0.001 
indicates a difference compared to the vehicle control  (6-OHDA; 0 µM). 
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4.4.4 GDNF or DNSP-11 pretreatment decreases 6-OHDA–induced caspase-3/7   
activity in SH-SY5Y cells. 
To investigate whether GDNF or DNSP-11 are able to prevent early apoptotic 
events induced by 6-OHDA in SH-SY5Y cells, caspase-3/7 activity was measured.  
Pretreatment with GDNF or DNSP-11 significantly inhibited 6-OHDA-induced caspase-
3/7 activation (Fig. 24). GDNF (50 ng/ml) produced a significant reduction in the 6-
OHDA-induced caspase-3/7 activity (Fig. 24). A significant decline in 6-OHDA-induced 
caspase-3/7 activity was also observed with 500 and 1000 ng/ml doses of DNSP-11 (Fig. 
24).The highest reduction in 6-OHDA-induced caspase-3/7 activity was observed with 
GDNF (50 ng/ml; 225%) as compared to 135 % and 134% reduction by 500 and 1000 
ng/ml DNSP-11, respectively  (Fig. 24). 
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Figure 24: GDNF and DNSP-11 reduced the 6-OHDA-induced increase in caspase-
3/7 activity 
SH-SY5Y cells were pretreated for 1 h with A) GDNF (0, 10 and 50 ng/ml) and B) 
DNSP-11 (0,1,10,100,500 and 1000 ng/ml) followed by 6-OHDA (100 µM; 30 min) 
treatment. The media containing 6-OHDA was removed, replaced with fresh media 
containing GDNF or DNSP-11, and a caspase-3/7 assay was performed 6 h post 6-OHDA 
removal.  Data are expressed as mean ± SEM. The data are averaged of triplicates from 3 
independent experiments. Statistical significance was determined by two-way ANOVA 
followed by the Bonferroni post hoc test. **** p < 0.0001 indicates a difference 
compared to the vehicle control (6-OHDA; 0 µM). ## p < 0.05 and #### p < 0.0001   
indicates a difference compared to the vehicle 6-OHDA (100 µM) treatment only. 
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4.4.5  GDNF and DNSP-11 activate ERK1/ 2 and ERK5 cellular signaling. 
 
To gain insight into GDNF and DNSP-11-mediated cellular mechanisms that may 
play a role in early protection against 6-OHDA toxicity, we investigated GDNF and 
DNSP-11-mediated activation of pro-survival cellular signaling.  SH-SY5Y cells were 
serum starved for 24 h and stimulated with GDNF or DNSP-11 for different time points.  
Treatment of SH-SY5Y cells with different concentrations of GDNF (10, 50, and 
100 ng/ml) increased the phosphorylation of ERK1/2 and ERK5 as compared to no 
treatment at 30, 60 and 120 min (Fig. 25A). Highest activation of these pathways was 
observed with 50 and 100 ng/ml doses of GDNF for all the time points (Fig. 25A).  
Hence, to determine the time course of ERK1/2 and ERK5 activation by GDNF, we used 
the 50 ng/ml dose of GDNF. GDNF (50 ng/ml) increased ERK1 and ERK2, and ERK5 
phosphorylation at the earliest measured time point (Fig. 25B). The activation of ERK1/2 
and ERK5 was sustained until 2 h and declined by baseline by 24 h (Fig. 25B).  
Similar to GDNF, DNSP-11 (1 µg/ml) activated ERK1/2 and ERK5 signaling 
(Fig. 25C). Increased ERK5 phosphorylation was observed starting at 5 min and was 
sustained up to 60 min (Fig. 25C). Interestingly, DNSP-11 mediated activation of 
ERK1/2 was more transient than that of ERK5 with maximum activation at 15 min. (Fig. 
25C).  
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Figure 25: GDNF and DNSP-11 activate ERK1, ERK2 and ERK5 cellular signaling 
SH-SY5Y cells were serum starved for 24 h and treated with A) GDNF (0, 10, 50 and 
100 ng/ml), B) GDNF (50 ng/ml) and C) DNSP-11 (1 µg/ml) for different time points.  
Cell lysates were collected and immunoblot analysis was performed to measure protein 
levels. Phosphorylation of ERK5 is indicated by an electrophoretic mobility shift of the 
ERK5 band.  
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4.4.6 Intrastriatal infusion of DNSP-11 modulates ERK signaling pathways and 
TH protein expression in the STR and SN. 
To gain insight into the effect of DNSP-11 on the ERKs cellular signaling in the 
dopaminergic regions in vivo, DNSP-11 was injected into the striatum. At different time 
intervals after DNSP-11 infusion, striatum and substantia nigra tissues were isolated and 
western blot analysis was performed to detect the modulation of ERKs and TH protein 
expression. 
In striatum 
There was no significant difference in basal ERK1, 2, and 5 levels in the STR 
from DNSP-11 treated animals versus control treated animals (Fig. 26). ERK5 
phosphorylation was not detected in this tissue region neither in control nor DNSP-11 
treatment group. Intrastriatal infusion of DNSP-11 did not activate ERK1 at any time 
point, while a significant decrease in ERK2 phosphorylation (33%) was observed at 6 h 
as compared to control (Fig. 26). A significant increase (42%) in TH expression with 
DNSP-11 treatment was observed at 7 day post DNSP-11 treatment (Fig. 28).   
In substantia nigra- 
There was no significant difference in basal and phosphorylated ERK1, 2, and 5 
levels in the SN from DNSP-11 treated animals versus control treated animals (Fig. 27). 
However, there was a trend towards an increase in basal ERK5 (33%) and 
phosphorylated ERK1 (32%) levels at 7 days and phosphorylated ERK2 (42%) at 2 h 
post DNSP-11 treatment (Fig. 27).  ERK5 phosphorylation was not detected in this tissue 
region neither in control nor DNSP-11 treatment group. A decline in TH expression 
(33%) with DNSP-11 treatment was observed at 2 h followed by 32% increase at 6 h post 
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DNSP-11 treatment (Fig. 28). At 24 h and 7 days following DNSP-11 infusion, no 
difference was observed in TH expression levels between DNSP-11 and control treated 
animals (Fig. 28). 
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Figure 26: Modulation of ERK1, ERK2, and ERK5 signaling by intrastriatal 
infusion of DNSP-11 in the STR 
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion, 
STR and SN tissues were isolated.  
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 in the 
STR.  
B) Quantification of the immunoblots was performed using Licor Odyssey software. The 
values are calculated using the integrated intensity. Protein expression was standardized 
to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean ± SEM. ^ p 
< 0.05 indicates a difference compared to the vehicle control. A two-tailed Student's t-test 
for unpaired data was also used for statistical comparisons.  2C - 2 h control; 2D - 2 h 
DNSP-11; 6C - 6 h control; 6D - 6 h DNSP-11; 
24C - 24 h control; 24D - 24 h DNSP-11; 7C – 7 days control; 7D – 7 days DNSP-11. 
117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
Figure 27: Modulation of ERK1, ERK2, and ERK5 signaling by intrastriatal 
infusion of DNSP in the SN 
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion, 
STR and SN tissues were isolated. 
A) Immunoblot analysis of total and phosphorylated ERK1, ERK2, and ERK5 in the SN. 
B) Quantification of the immunoblots was performed using Licor Odyssey software. The 
values are calculated using the integrated intensity. Protein expression was standardized 
to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean ± SEM. A 
two-tailed Student's t-test for unpaired data was also used for statistical comparisons. 2C 
- 2 h control; 2D - 2 h DNSP-11; 6C - 6 h control; 6D - 6 h DNSP-11; 24C - 24 h control; 
24D - 24 h DNSP-11; 7C – 7 days control; 7D – 7 days DNSP-11. 
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Figure 28: Modulation of TH protein expression by intrastriatal infusion of DNSP-
11 in the STR and SN 
DNSP-11 (30 µg) was infused into STR. Two hours, 6 h, 24 h and 7 days post infusion, 
STR and SN tissues were isolated. Immunoblot analysis of TH expression in the STR and 
SN. Quantification of the immunoblots was performed using Licor Odyssey software. 
The values are calculated using the integrated intensity. Protein expression was 
standardized to the intensity of α-Tubulin. n = 5 for each age. Data are expressed as mean 
± SEM. ^^ p < 0.01 indicates a difference compared to the vehicle control. A two-tailed 
Student's t-test for unpaired data was also used for statistical comparisons.   
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4.5  Discussion 
 
DNSP-11, an endopeptidase cleavage product from the human GDNF 
prosequence, has been shown to possess neurotrophic and neuroprotective properties of 
GDNF (Fuqua, 2010; Bradley et al., 2010, Sonne, 2013). For example, DNSP-11 has 
been shown to protect dopaminergic cells against neurotoxin-induced toxicity in vitro and 
in vivo (Bradley et al., 2010, 2013; Sonne, 2013). More specifically, Bradley and 
colleagues (2010) used MN9D cells to study the effect of DNSP-11 pretreatment on 6-
OHDA-induced toxicity and they found that pretreatment with DNSP-11 significantly 
inhibited the 6-OHDA-induced increase in apoptosis and caspase-3 activity (Bradley et 
al., 2010).  
Another widely used cellular model of dopaminergic neurons is SH-SY5Y cells. 
SH-SY5Y cells express many features of DA neurons and are widely used to study 
neuroprotective properties of phytochemicals, neurotrophins, and growth factors.  Hence, 
in the current study the effects of DNSP-11 and GDNF were examined in SH-SY5Y 
cells. As seen in figure 20A, 6-OHDA treatment induced a concentration-dependent 
decrease in SH-SY5Y cell viability. At 100 µM, 6-OHDA reduced cell viability by 
approximately 50% when measured by the CTG assay (Fig. 21).  Pretreatment with 
GDNF (Fig. 22A) or DNSP-11 (Fig. 22B) did not decrease the 6-OHDA-induced loss of 
cell viability when measured at 24 h using the CTG assay. Failure of GDNF to block 6-
OHDA-induced cell loss has also been observed by others (Kramer et al., 1999, Ding et 
al., 2004). For example, Ugarte and colleagues (2003) failed to observe GDNF-mediated 
protection against 6-OHDA-induced cell death at 24 h using a trypan blue exclusion 
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assay. GDNF was also not able to protect embryonic mesencephalic dopamine neuronal 
cultures against 6-OHDA toxicity at time periods greater than 24 h (Kramer et al., 1999).  
In contrast to assays that measure generalized cell death, GDNF and DNSP-11 
protected against 6-OHDA–induced apoptotic events when assays that detect apoptotic 
events, such as nuclear condensation and fragmentation, TUNEL assays, and caspase-3/7 
assays were used (Ugarte et al., 2003, Bradley, et al., 2010).  These data suggest that 
GDNF blocks some, but not all, of the cytotoxic effects of 6-OHDA. Another important 
point to be noted from previous studies is that GDNF and DNSP-11 protected against 6-
OHDA toxicity at early time points (i.e. < 24 h) following 6-OHDA treatment (Bradley et 
al., 2010, 2013). Therefore, we determined whether GDNF or DNSP-11 is able to block 
early apoptotic signaling events, such as caspase-3/7 activity. Increase in caspase-3/7 
activity has been associated with apoptotic cell death. As seen in figure 24, pretreatment 
with GDNF or DNSP-11 significantly reduced 6-OHDA-induced caspase-3/7 activity. 
GDNF caused a 225% reduction in caspase-3/7 activity versus a 135 % reduction by 
DNSP-11 (Fig. 24). This observed decrease in caspase activity with GDNF and DNSP-11 
against neurotoxin is in accordance with a study by Bradley and colleagues (2010, 2013). 
The ability of GDNF and DNSP-11 to reduce 6-OHDA-induced capase-3/7 activity, 
which is an early apoptotic event, while they are unable to provide protection against cell 
death at later times (≥ 24 h), could be attributed to 6-OHDA-induced damage to the outer 
membrane of mitochondria and various organelles that overcome the early beneficial 
effects of GDNF and DNSP-11. Secondly, GDNF and DNSP-11 might have only short 
term effects for several reasons. For example, supporting cells, such as glia, may be 
required for these agents to provide neuroprotective effects and/or anti-apoptotic cellular 
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signaling pathways may only be transiently activated by GDNF and DNSP-11. The 
difference in the doses of GDNF and DNSP-11, at which the protective effect is 
observed, with respect to reduction in caspase-3/7 activity, could be associated with the 
differences in amplification and activation of protective cellular protective mechanisms. 
The GDNF-mediated activation of protective cellular signaling through GFRα1/RET 
receptor signaling pathway is well studied, whereas, the mode of DNSP-11-mediated 
cellular protection is not well studied and it’s under investigation. Differences in the 
function of DNSP-11 and GDNF have been already shown (Bradley et al., 2010). No 
dose-dependent significant difference in the reduction of 6-OHDA-induced caspase-3/7 
activity observed at DNSP-11 (500 and 1000 ng/ml) in the SH-SY5Y. This may be 
associated with saturation of protective cellular signaling activation. 
To investigate the effect of GDNF and DNSP- on pro-survival signaling 
pathways, ERK1, 2, and 5 signaling was examined in the SH-SY5Y cells. ERK1, 2, and 5 
were chosen as they have been shown to decrease oxidative stress-induced dopamine 
neuronal cell death (Ugarte et al., 2003; Cavanaugh et al., 2006). Treatment of SH-SY5Y 
cells with GDNF or DNSP-11 increased the phosphorylation of ERK1, 2, and 5 starting 
at early time points (Fig. 25B and 25C). GDNF treatment caused a sustained activation of 
ERK1, 2, and 5 (Fig. 25A-25B), while DNSP-11 treatment transiently increased ERK1 
and 2 phosphorylation (Fig. 25C). This difference may be associated with differences in 
mode of activation of these cellular signaling. As previously mentioned, GDNF acts 
through GFRα-/RET receptor mechanism; however, so far DNSP-11 appears to be less 
likely act through this receptor mechanism (Bradley et al., 2010) and understanding of 
DNSP-11 mode of action is required to address this difference. Similar to GDNF, DNSP-
123 
 
11 caused a sustained increase in ERK5 phosphorylation (Fig. 25C). Therefore, the 
GDNF and DNSP-11-mediated reduction in oxidative stress-induced caspase-3/7 activity 
may be attributed to ERK1, 2, and 5 activation. Activation of ERK signaling has been 
shown to prevent apoptosis through suppression of caspase activity either by upregulation 
of anti-apoptotic proteins, such as Bcl-2 and Bcl-w, and/or downregulation of apoptotic 
proteins, such as Bim (that are present at mitochondrial membrane) (O’Connor et al., 
1998; Ley et al., 2003; Pazyra-Murphy et al., 2009; Roberts et al., 2010; Wang et al., 
2013), thereby, preventing loss of mitochondrial outer membrane potential and release of 
cytochrome c, which activates caspases. 
DNSP-11 has profound effects in animal models of PD and has been shown to 
possess neuroprotective and neurorestorative properties in the nigrostriatal system 
(Bradley et al., 2010; Sonne, 2013). A single infusion of the DNSP-11 in the SN led to an 
increase in dopamine, DOPAC, and HVA in the STR (Bradley et al., 2010). To 
understand the molecular events that are activated by DNSP-11 in vivo, we infused a 
single dose of DNSP-11(30 µg) into the STR and examined the effect on ERK signaling 
in the nigrostriatal system. In the STR, a significant decline in ERK2 phosphorylation 
(33%) was observed at 6 h post DNSP-11 treatment with no change in any other basal or 
phosphorylated ERK proteins at any other time points detected (Fig. 26). In the SN, a 
trend increase in phosphorylation of ERK1 and 2 was observed (Fig. 27). Additionally, 
although not significant, a 42% and 32% rise in TH levels in the STR and SN, 
respectively, were observed after DNSP-11 treatment (Fig. 28).  The decrease in TH 
expression observed at 2 h in SN (Fig. 28) could be associated with increase in 
phosphorylated TH form, resulting in decline in basal TH level. To test this hypothesis, 
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levels of p-TH need to be analyzed using western blot analysis.  As the DNSP-11 was 
infused in the striatum, it is possible that retrograde transportation of DNSP-11 from the 
STR (dopamine nerve terminal containging region) to the SN (dopamine cell body 
containing region) may have occurred to increase ERK1 and 2 phosphorylation and TH 
expression. Similar to the current study, modulation of ERK1 and ERK2 activation and 
TH levels have been observed in the SN after intrastriatal infusion of neurotrophic 
factors, such as GDNF and BDNF  (Mufson et al., 1994; Salvatore et al., 2004, Lindgren 
et al., 2008, 2012). Retrograde transportation of GDNF from the nerve terminal to cell 
body, thereby, activation of cellular signaling in the cell body has been shown to be 
associated with receptor machinery, involving GFRα -1 (Coulpier et al., 2004). 
Tyrosine hydroxylase has shown to regulate DA bioavailability (Salvatore et al., 
2009). Therefore, the rise in TH expression in the STR may underlie the increase in 
striatal dopamine levels observed with DNSP-11 treatment in the previous study by 
Bradley and colleagues (2010).  
In conclusion, DNSP-11 was not able to protect SH-SY5Y cells against 6-OHDA-
induced toxicity, when viability was measeured at 24 h. However, significant reduction in 
6-OHDA-induced caspase 3/7 activity was observed with DNSP-11 at early time points. 
In SH-SY5Y cells, DNPS-11 treatment leads to increase in ERK1/2, and ERK5 
activation. Collectively, the anti-apoptotic properties of DNSP-11 in dopaminergic SH-
SY5Y cells, along with its ability to modulate ERK1, 2, and TH in dopaminergic brain 
regions, in vivo, are analogous to GDNF and suggest that is may be a good therapeutic 
candidate for PD. 
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Chapter 5: Conclusions and Future directions 
 
With normal aging dysfunctioning in dopaminergic system, especially nigrostrital 
system has been observed, that have shown to be resulted in motor deficits, parkinsonium 
symptoms, and increased risk and development of PD. Age-related degeneration of the 
nigrostriatal system has been observed as indicated by loss of dopamine neurons in the 
SN, decline in DA tissue and extracellular levels in SN and STR, and loss of 
dopaminergic neuronal function. A better understanding of changes in the pro-survival 
cellular signaling kinases (ERK1, 2, and 5), known to protect DA neurons against toxins, 
in these dopaminergic regions will provide an insight into their mechanistic role in 
dopamine neuronal survival.  
In this work, a decline in ERK5 activation with age in the SN and STR 
dopaminergic regions was observed. Higher expression of ERK5 was observed in these 
regions during early postnatal day, which decline with postnatal development. 
Concomitant expression of ERK1and ERK2 was low at early postnatal day, which 
increased with postnatal development. When ERK5 signaling was blocked, it resulted 
into early loss of DA neurons. These findings suggest the possibility that ERK5 signaling 
is crucial for the basal dopamine neuronal survival during early postnatal development 
and during aging. Secondly, it also suggests that a loss of ERK5 signaling in the 
dopaminergic regions, SN and STR, may contribute to the normal age-related decline of 
nigrostriatal dopaminergic function and possibly to the pathogenesis of age-related 
neurodegenerative disorders such as Parkinson’s disease. It will be important to 
investigate the ERK5 expression change in the aged and PD human brain samples, along 
with conditionally knocking down ERK5 signaling in the dopaminergic system of rodents 
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and measuring its outcomes in terms of motor deficits, DA neuronal physiology , and 
function. It will be also important to elucidate the reasons for the age-related reduction in 
ERK5 in these regions; whether they are associated with age-related alteration in 
neurotrophic factors or reduction in receptor-mediated amplification or activation of 
cellular signaling.  
Compared to previous studies, neuroprotective mechanisms of GDNF and DNSP-
11 against 6-OHDA-induced toxicity were evaluated in the human dopaminergic 
neuroblastoma SH-SY5Y cell line.  Neurotrophic factor GDNF and its propeptide DNSP-
11 were able to activate pro-survival ERK1, 2, and 5 kinases. Infusion of DNSP-11 into 
the STR resulted into modulation of ERK1, 2, and 5 signaling, along with TH protein 
expression not only in the STR, but also in SN. Hence, as future direction, it will valuable 
to evaluate whether DNSP-11 infusion into the STR leads to its retrograde signaling from 
DA nerve terminal into the DA cell bodies in the SN. Effect of DNSP-11 on the 
phosphorylation states of TH are still need to be studied, which would address increase in 
DA levels in the STR and SN on DNSP-11 infusion.  In order to elucidate distinct role of 
ERK1, 2, and 5 in the dopaminergic system development conditional knockdown of 
ERK1, 2, and 5 will be necessitated.  Further, it will be important to determine whether 
GDNF and DNSP-11 mediated protection of dopaminergic neurons against neurotoxins-
induced oxidative stress, in vivo or in vitro involve protective ERK5 signaling.  
 With the increase in aging population and increased risk of development of 
neurodegenerative diseases, such as PD, it becomes important to understand the 
alterations in cellular signaling pathways that are crucial for neuronal survival during 
development and with aging. Understanding the modulation of cellular signaling 
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pathways and molecular mechanisms involved in neuronal death with aging, such as DA 
neuronal cell death in PD, will help to design therapeutic treatments to activate these 
protective cellular signaling, thereby preventing the loss of neuron. This dissertation 
addresses the importance of MAPK kinase signaling proteins, ERK1, 2, and 5 for the DA 
neuronal survival and activation of these kinases by promising neurotrophic factor, 
GDNF, and its pro-peptide molecule, DNSP-11.  
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